Screening method based on tsap 6 binding partners

ABSTRACT

The invention concerns methods for detecting, identifying and/or screening compounds in particular for use in treating cancers and certain neurodegenerative diseases related to dysfunction in tumour suppression regulation and/or apoptosis, in the biological chain of p53, said methods being based on interaction between TSAP6 and its binding partners identified in the present invention.

[0001] The present invention relates to methods for detecting, identifying and/or screening compounds which may in particular be used for treating cancers or some neurodegenerative diseases related to dysfunction in the regulation of tumor reversion/suppression and/or apoptosis, in the p53 biological pathway.

[0002] Apoptosis, or cell death, is a complex phenomenon which is regulated by many proteins, including p53. This protein interacts with many other proteins, and its expression, which induces the phenomena of cell death and of tumor reversion, can be correlated with the induction or the suppression of expression of other cellular genes.

[0003] The inventors of the present invention have thus demonstrated genes which are induced and activated during the cascade leading to tumor reversion and/or apoptosis (TSAP for “Tumor Suppressor Activated Pathway”), or genes which are suppressed (TSIP for “Tumor Suppressor Inhibited Pathway”). These genes have in particular been the subject of patent application WO 97/22695 or WO 00/08147.

[0004] It is important to be able to understand precisely the mechanisms of the p53 cascade, in order to be able to generate new compounds having antitumor activity (which can in particular induce apoptosis or tumor suppression), or which can be used for the treatment of neurodegenerative diseases. Specifically, the inventors of the present application have demonstrated that presenilin 1 (PS1), the role of which in Alzheimer's disease had been suggested, is identical to the TSIP 2 protein described in application WO 97/22695. Thus, it is legitimate to search for medicinal products which can interfere in apoptosis, in order to reduce this phenomenon, and which might be used in neurodegenerative diseases.

[0005] The present invention relates to methods for screening and identifying products which can interfere in the p53 cascade and thus induce tumor reversion and/or apoptosis or, conversely, decrease the phenomena of apoptosis.

[0006] The present invention is based on the interactions of the TSAP6 protein with other proteins, as demonstrated by the inventors of the present application. The TSAP6 protein, described in patent application WO 97/22695, and in GenBank under the number U50961, is a protein with six transmembrane domains, which suggests that it is located in a cell membrane. Thus, it is reasonable to think that the TSAP6 protein can act as a receptor in the metabolism for regulating p53-associated apoptosis, and that determining its binding partners may prove to be important with regard to the overall understanding of the regulation of apoptosis/tumor reversion in cells.

[0007] The nucleotide sequence of murine TSAP6 is represented by SEQ ID No 49 and the open reading frame of the protein corresponds to SEQ ID No 50.

[0008] The nucleotide sequence of human TSAP6 is represented by SEQ ID No 51 and the open reading frame of the protein corresponds to SEQ ID No 52.

[0009] Thus, in a first embodiment, the present invention relates to methods of screening and/or selecting or identifying a compound which interferes with, reduces or inhibits the binding of TSAP6 to one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, having the steps of:

[0010] a) bringing said compound into contact with a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48;

[0011] b) identifying the decrease in and/or the inhibition of the binding between TSAP6 and said protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48.

[0012] In order to determine compounds which make it possible to increase tumor reversion and/or cell death (apoptosis), it is also possible to define a method according to the invention, in particular a method for screening, selecting or identifying compounds whose function is an increase in tumor reversion and/or cell death (apoptosis), having the steps of:

[0013] a) bringing said compound into contact with a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48;

[0014] b) identifying the compounds which induce the decrease in and/or the inhibition of the binding between TSAP6 and said protein defined in a);

[0015] c) bringing the compounds selected in step b) into contact in a system for measuring the phenomena of apoptosis and/or of tumor reversion;

[0016] d) identifying the increase in tumor reversion and/or in cell death (apoptosis) in said model by comparison with a control model with which said compound has not been brought into contact.

[0017] Such a method is therefore also a subject of the present invention.

[0018] The subject of the present invention is also a method for screening, selecting or identifying compounds whose function is a decrease in and/or the inhibition of tumor reversion and/or cell death (apoptosis), having the steps of:

[0019] a) bringing said compound into contact with a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48;

[0020] b) identifying the compounds which induce the decrease in and/or the inhibition of the binding between TSAP6 and said protein defined in a);

[0021] c) bringing the compounds selected in step b) into contact in a system for measuring the phenomena of apoptosis and/or of tumor reversion;

[0022] d) identifying the decrease in and/or the inhibition of tumor reversion and/or cell death (apoptosis) in said model by comparison with a control model with which said compound has not been brought into contact.

[0023] The present invention therefore uses the fact that the TSAP6 proteins and the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44 or 46, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 45 or 47, can bind to one another. It is therefore advantageous to identify the domains of each protein which are effectively in contact with the other protein. As a result, this should make it possible to be able to use the peptides thus identified as decoys or agonists for the complete proteins. This may thus make it possible to define compounds which will interfere in the binding between TSAP6 and one of the proteins chosen from-SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, and which may either induce tumor suppression and/or apoptosis or, conversely, decrease these phenomena.

[0024] A subject of the present invention is therefore in particular a method for identifying a region of TSAP6 which binds with one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, comprising the steps of:

[0025] a) bringing peptides derived from the TSAP6 protein into contact in a system for evaluating the binding of the TSAP6 protein with said protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48;

[0026] b) identifying the peptides which induce the decrease in the binding between the TSAP6 protein and said protein defined in a) by comparison with the binding observed between TSAP6 and said protein defined in a), when said peptides are absent from the system.

[0027] The term “region of TSAP6 ” is in particular intended to mean peptides with a primary sequence derived from the primary sequence of the TSAP6 protein.

[0028] A subject of the present invention is also of course the methods for identifying the regions of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44 or 46, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 45 or 47, which binds with TSAP6.

[0029] The system envisioned can be implemented in vitro or in vivo.

[0030] Thus, the present invention makes it possible to identify regions of TSAP6 which are involved in the binding with one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, using a method comprising the steps of:

[0031] a) bringing peptides derived from the TSAP6 protein into contact in a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48;

[0032] b) identifying the peptides which lead to the decrease in the binding between TSAP6 and said protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, in said system.

[0033] It is obvious that the present invention also makes it possible to determine the regions of one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, which are involved in the binding with TSAP6, according to methods similar to the methods described above, and that these regions can in particular be used as decoys when the intention is to decrease tumor reversion and/or apoptosis.

[0034] The present invention therefore makes it possible to identify products which make it possible to interact with the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, and which may therefore be of value in the regulation of apoptosis and/or tumor reversion. However, it is possible that these products, in order to be able to be used for a therapeutic treatment, in particular in cancer or neurodegenerative diseases, need to be optimized in order to have greater activity and/or less toxicity.

[0035] In fact, a medicinal product is often developed according to the following principle:

[0036] screening of compounds having a desired activity using a suitable method,

[0037] selection of the compounds corresponding to the “specifications”,

[0038] determination of the structure (in particular the (optionally tertiary) sequence if they are peptides, formula and backbone if they are chemical compounds) of the compounds selected,

[0039] optimization of the compounds selected, by modification of the structure (for example by changing the stereochemical conformation (for example changing from L to D for the amino acids in a peptide), addition of substituents to the peptide or chemical backbones, in particular by grafting residues onto the backbone, modification of the peptides (see in particular Gante (“Peptidomimetics”, in Angewandte Chemie-International Edition Engl. 1994, 33. 1699-1720)),

[0040] passage and screening of the compounds thus obtained on suitable models which are often models closer to the pathology condition studied. At this stage, animal models, in general in rodents (mice, rats, etc.) or in dogs, or even primates, are in particular often used.

[0041] The animal models which can be used are for example, for cancer, models based on immunodepressed mice (for example scid/scid), into which tumor cells are injected (in particular subcutaneously), which cells will lead to the development of tumors. The effectiveness of the potentially antitumor compounds is studied, for example by measuring the size of the tumors formed.

[0042] For studying neurodegenerative diseases, the model described by Amson et al. (2000, Proc. Natl. Acad. Sci. USA, 97, 5346-50), which consists of p53-deficient mice, or the model described in Chen et al., Janus et al., and Morgan et al. (2000, Nature, 408 pp. 975-985) can be used.

[0043] Thus, a object of the present invention is in particular to make it possible to identify compounds which might be used for treating cancer in that they have an activity of increasing tumor reversion and/or apoptosis. One of the subjects of the present invention is therefore a method comprising the steps of:

[0044] a) implementing a method according to the invention which makes it possible to identify compounds having a certain activity of increasing tumor reversion and/or apoptosis, and/or of inhibiting the binding between TSAP 6 and a protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48,

[0045] b) modifying the product selected in step a),

[0046] c) testing the product modified in step b) in in vitro and/or in vivo methods on relevant models of tumor reversion and/or apoptosis,

[0047] d) identifying the product which makes it possible to obtain an activity of tumor reversion and/or apoptosis greater than the activity obtained for the product selected in step a).

[0048] Step d) can be replaced with a step d′), which would be:

[0049] d′) identifying the product which makes it possible to obtain the desired biological effect with less toxicity in an animal model (when one of the models used in step c) is in vivo).

[0050] When the tests are carried out on models of apoptosis or tumor reversion in vitro, the K256/KS model described by Tellerman et al. (1993, Proc. Natl. Acad. Sci. USA, 90, 8702-6) can for example be used. The M1-LTR cells described by Amson et al. (1996, Proc. Natl. Acad. SCI; USA, 93, 3953-7), or the U937/US3-US4 cells described by Nemani et al. (1996, Proc. Natl. Acad. Sci. USA, 93, 9039-42), can also be used.

[0051] The in vivo trials can be carried out by injecting these cells into animals (in particular immunodepressed mice), and studying the effects of the various compounds tested.

[0052] Those skilled in the art will be able to define the conditions and the thresholds necessary for identifying a product which can be used as a medicinal product, according to the regulatory requirements (in particular for toxicology), with respect to the benefit provided by the product thus identified.

[0053] Similarly, the invention also relates to the methods for optimizing the products which suppress tumor reversion and/or apoptosis, identified using the methods described above, and making it possible to identify products which can be used as medicinal products.

[0054] Thus, the invention also relates to a method for identifying a product having an activity of decreasing and/or inhibiting tumor reversion and/or apoptosis, characterized in that it comprises the steps of:

[0055] a) implementing a method according to the invention which makes it possible to identify compounds having a certain activity of decreasing tumor reversion and/or apoptosis, and/or of inhibiting the binding between TSAP6 and a protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48,

[0056] b) modifying the product selected in step a), in particular by grafting residues onto the chemical backbone,

[0057] c) testing the product modified in step b) in in vitro and/or in vivo methods, on relevant models of tumor reversion and/or apoptosis,

[0058] d) identifying the product which makes it possible to obtain an activity of tumor reversion and/or apoptosis which is decreased compared to the activity obtained for the product selected in step a).

[0059] Step d) can also be replaced with a step d′), which would be:

[0060] d′) identifying the product which makes it possible to obtain the desired biological effect with less toxicity in an animal model (when one of the models used in step c) is in vivo).

[0061] This in fact again involves being able to obtain the product which exhibits the best (biological activity and clinical effect)/(potential risks for use) ratio.

[0062] The parameters to be brought into play for obtaining these results are all known and within the scope of those skilled in the art who wish to develop new medicinal products, and can be found, for example, in the directives of the organizations such as the Agence du Médicament [French Drug Agency], the European Commission or the Federal Drug Agency.

[0063] The implementation of the methods according to the present invention requires models which make it possible to determine the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48.

[0064] When the methods according to the invention are implemented on in vitro models, there are several ways in which the binding between one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, and TSAP6 can be studied.

[0065] A protocol which can be used may be as follows:

[0066] expression and purification of the TSAP6 proteins and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, for example in prokaryotic cells (E. coli, B. subtilis, etc.) or eukaryotic cells (yeast such as Saccharomyces, Kluyveromyces, etc.), mammalian cells (HeLa, Cos, Hep-2, etc.) or insect cells (using a Baculovirus system). It may be advantageous for the proteins to have a tag at their N- or C-terminal end, in order to facilitate purification. A histidine or GST tag is in particular chosen. These methods are well known to those skilled in the art, who can find the suitable plasmids in the catalogues of companies such as Stratagéne;

[0067] binding of the proteins to suitable beads. When a GST tag is used, the proteins expressed are bound to sepharose beads exhibiting glutathione;

[0068] preparation of proteins by in vitro translation. This can easily be carried out using commercial vectors (for example available from Promega), which make it possible to clone the cDNAs under the control of well-known promoters (T7 or T3), and to use suitable RNA polymerases to produce the RNAs, and then to carry out expression of the proteins in vitro, using available kits and following the manufacturer's indications;

[0069] Coprecipitation of the proteins, by adding the proteins obtained by in vitro translation to the sepharose-glutathione beads to which the proteins from fusion with GST are attached. After a sufficient amount of contact time, the beads are washed and analysis by SDS-PAGE gel electrophoresis and autoradiography is carried out. The appearance of the bands corresponding to the two proteins clearly shows binding between them.

[0070] The use of suitable controls thus makes it possible to define the decrease in and/or the inhibition of the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, by comparing the amounts of proteins released after addition of the compound tested during the coprecipitation step, with the amounts of proteins released in the controls.

[0071] The binding of the proteins can also be studied using the FRET (Fluorescence Resonance Energy Transfer) system, which consists in labeling each of the proteins with a suitable residue, the binding of the two proteins inducing a reaction between each of the two residues and emission of a readily detectable fluorescence.

[0072] A subject of the present invention is also the compounds which can be obtained using a method according to the invention, in particular the compounds having an activity of increasing tumor reversion and/or apoptosis, those having an activity of inhibiting the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, and also those having an activity of decreasing and/or inhibiting tumor reversion and/or apoptosis.

[0073] The present invention also relates to the peptide sequences corresponding to a region of TSAP6 which interacts with one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, which can in particular be identified using a method according to the invention.

[0074] The invention also relates to the peptide sequences corresponding to a region of one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, which interacts with the TSAP6 protein, which can in particular be identified using a method according to the invention, the method which makes it possible to identify the peptide sequences of TSAP6 which interact with one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, possibly being adapted to determine the peptide sequences of one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, which interacts with TSAP6, in particular by adapting the in vitro protocol developed above.

[0075] The invention also relates to the nucleotide sequences encoding the peptide sequences thus identified.

[0076] It is clear that the term “peptide sequence” or “nucleic acid sequence” or “nucleotide sequence” (the latter two terms being used indifferently) represents sequences which are isolated, i.e. which are outside their natural state, and can in particular be modified by replacement of their base units with unnatural units, or by modification of the bonds between the base units (for example phosphorothioates (nucleic acid) or Peptide Nucleic Acids).

[0077] An object of the present invention is therefore in particular to make it possible to identify compounds which interfere with the binding of TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, some of these compounds being able in particular to induce effects on the p53 cascade. Thus, the compounds according to the invention, the peptide sequences according to the invention or the nucleotide sequences according to the invention, as a medicinal product, are also subjects of the invention.

[0078] A compound identified using a method according to the invention may be a compound which has a chemical structure, a lipid, a sugar, a protein, a peptide, a protein-lipid, protein-sugar, peptide-lipid or peptide-sugar hybrid compound, or a protein or a peptide to which chemical branches have been added.

[0079] Among the chemical compounds envisioned, they may contain one or more (in particular 2 or 3) rings, which may or may not be aromatic, having from 3 to 8 carbon atoms, and also several residues of any type (in particular lower alkyl, i.e. having between 1 and 6 carbon atoms).

[0080] These compounds, nucleic acid sequences and peptide sequences can thus be used, according to the invention, for preparing a medicinal product intended in particular for the treatment of cancer or a neurodegenerative disease, depending on the pro- or anti-apoptosis/tumor reversion effect.

[0081] The inventors of the present application have, for the first time, demonstrated the fact that the TSAP6 protein binds to one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48. Thus, the present invention also relates to a complex consisting of a TSAP6 protein and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48.

[0082] The present invention also relates to a method for inhibiting the binding of TSAP6 to one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, in a cell, comprising the step of:

[0083] a) bringing said cell into contact with a compound identified using a method according to the invention, which inhibits the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48.

[0084] The compound thus envisioned can also be a “decoy” peptide derived from the TSAP6 protein or from one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48. The method can be implemented in vitro or in vivo.

[0085] The present invention is also directed toward a method for treating a cancer, characterized in that a compound which has been identified according to the present invention and which increases apoptosis and/or tumor reversion is administered to a patient.

[0086] A method for treating a neurodegenerative disease, consisting in administering, to a patient, a compound according to the present invention which decreases or inhibits apoptosis, is also a subject of the present invention.

FIGURE LEGENDS

[0087]FIG. 1: TSAP6 colocalizes in the endoplasmic reticulum and golgi

[0088] Hela cells transfected with GFP-TSAP6 were analyzed for their subcellular location. Hela cells overexpressing GFP-TSAP6 were colabeled with markers specific for the endoplasmic reticulum (ER), for the golgi, for the mitochondria (mito) and for the nucleus (nuclei). This type of labeling revealed that the subcellular location of TSAP6 is inside the endoplasmic reticulum and the golgi. It should also be noted that TSAP6 also appears to be expressed on the plasma and nuclear membranes.

[0089]FIG. 2: TSAP6 antisense prevents p53 induced cell death in TS LTR6 cells

[0090] A. Western blotting analysis indicates that the endogenous protein levels for TSAP6 are decreased 24 h after induction by p53 in LTR6 cells overexpressing anti-TSAP6.

[0091] B. Overexpression of the TSAP6 antisense (as2) delays the apoptosis induced by activation with p53. The analysis of the evolution over time of LTR6 and LTR6-as2 according to temperature changes at 32° C.

[0092] C. Two-color flow cytometry analysis of the LTR6 and LTR6-as2 cells. Cells were labeled with annexin-V and propidium iodide (PI). The LTR6-as2 cells express the annexin-V and annexin-V/PI less compared to the LTR6 cells, indicating that the TSAP6 antisense prevents the p53-induced apoptosis.

[0093] D. LTR6-as2 and -as4 prevent p53-induced PARP cleavage. Total lysates from the experiments above were analyzed for PARP cleavage, a marker for apoptosis, with an anti-PARP antibody. Compared to the LTR6 cells, LTR6-as2 and -as4 show a marked decrease in PARP 8 hours after activation with p53.

[0094]FIG. 3: TSAP6 binds with Nix and Myt1 in vitro and in vivo

[0095] A. Analyses of a layer of yeast revealed that TSAP6 interacts with Nix and Myt1.

[0096] B. Interaction in vitro of either GST-Nix or GST-Myt1-150 with TSAP6 radiolabeled during in vitro translation (IVT). The GST-Nix or GST-Myt1-150 is incubated with TSAP6 transcribed/translated and radiolabeled in vitro. GST-NKTR and AIP1 labeled by IVT are also included as a negative control. These analyses revealed that GST-Nix and GST-Myt1-150 bound specifically with TSAP6. In addition, mapping experiments revealed that Nix and Myt1 interact with a fragment of TSAP6 composed of amino acids 1 to 316.

[0097] C. Interaction in vivo of Ha-TSAP6 with Flag-Nix (left panel) and Flag-Myt1-150 (right panel) in 293T cells. 293T cells were transfected with the indicated combination of plasmids and TSAP6 immunoprecipitated with an anti-HA antibody. A Nix and Myt1-150 interaction was revealed with an anti-Flag antibody.

[0098] D. Colocalization of GFP-TSAP6 and Flag-Myt1. Hela cells overexpressing GFP-TSAP6 (left panel) and Flag-Myt1 (middle panel) were analyzed with a confocal microscope for colocalization (right panel). This analysis indicates that TSAP6 and Myt1 are colocalized.

[0099]FIG. 4: TSAP6 cooperates with Nix to promote cell death

[0100] A. Hela 39 and 51 cells overexpressing HA-TSAP6. Western blotting analysis using an anti-HA on Hela cells in order to detect TSAP6.

[0101] B. Overexpression of TSAP6 promotes retarded cell growth and apoptosis. Analysis of cell growth (left panel). The Hela cells or the Hela cells expressing either a control vector or TSAP6 (39 and 51) were labeled with trypan blue and the cell viability was determined at the times indicated. Analysis of cell death (right panel): the cell death was determined by counting cells which had incorporated trypan blue.

[0102] C. Exacerbation of apoptosis in the Hela-51 cells overexpressing Nix. A Hela vector or Hela-51 cells were transfected with Flag constructs containing the negative control AIP1, Nix or the pro-apoptotic molecule Bid-t, which was used as a positive control. 24 hours after transfection, the cells were labeled with an anti-flag antibody so as to detect the overexpressed proteins, and with DAPI, a nuclear stain, and the cells were then counted. This analysis showed that, while AIP1 had a minimal effect on apoptosis in any cell line, overexpression of Nix greatly stimulated cell death in the cells overexpressing TSAP6. On the other hand, Bid-t promoted similar levels of apoptosis independently of the cell line.

[0103] D. Overexpression of Nix in Hela-51 greatly promotes PARP cleavage. Total lysates from the preceding experiments were analyzed by Western blotting using an anti-PARP antibody. This analysis shows that Nix and TSAP6 cooperate together to promote levels of PARP cleavage (below). The TSAP6 antisense prevents the Nix-induced PARP cleavage in 293T cells. 293T cells were transfected with the plasmids indicated and, 24 hours later, cell lysates were prepared and the PARP cleavage was analyzed by immunolabeling with an anti-PARP antibody. These data show that, while Nix alone promotes partial cleavage of PARP, the addition of a TSAP6 antisense completely blocks this effect.

[0104] E. Colocalization of GFP-TSAP6 and Nix after treatment with staurosporine. Hela cells transfected with TSAP6 (left panel) and Nix (middle panel) were analyzed with a confocal microscope 24 hours later. While colocalization of TSAP6 and Nix (right panel) was difficult to detect (-stauro), induction of apoptosis with staurosporine promoted coalescence of TSAP6 and Nix.

[0105]FIG. 5: Overexpression of TSAP6 promotes the delaying of the cell cycle in G2 by preventing dephosphoryation of cdc2

[0106] A. Double thymidine block analysis reveals that the Hela-51 cells contain an additional G2/M-population. A DTB procedure was carried out and a Hela vector and Hela-51 cells were analyzed in the times indicated with regard to their progression in the cell cycle. An analysis by flow cytometry was carried out on cells labeled with propidium iodide with the aim of revealing the various steps of the cell cycle. At. t=0, the Hela-51 cells showed an additional population of cells corresponding to G2/M. At t=12 hours, the Hela-51 cells contained a notable accumulation of these G2/M cells, at a time when the majority of Hela-vector cells are returning to stage G1.

[0107] B. H3 histone labeling at t=0 and t=12 hours after the release of DTB. The analysis by flow cytometry was carried out on cells labeled with an anti-H3 phosphohistone antibody, which labels cells in mitosis, and with propidium iodide. This analysis revealed that, while the majority of the Hela-51 cells exhibited a G2/M phenotype (approximately 60%) after 12 hours, only approximately 15% of the G2/M cells exhibited an H3⁺phenotype. This is in contrast with the Hela vector cells having G2/M, 20% of which are in mitosis at the same time.

[0108] C. Analysis of the mitotic index of the Hela-vector and Hela-51 cells. These results revealed that the Hela-51 cells have a delayed entry into mitosis compared to the Hela vector cells. In addition, these data confirm the results above according to which overexpression of TSAP6 delays rather than favors the progression of the cell cycle. The Hela cells were synchronized with DTB and, at the times indicated, the cells were fixed and stained with Giemsa-Wright stain with the aim of detecting the chromosomal condensations. At least 600 nuclei were counted for each time point.

[0109] D. Brdu labeling of the Hela-vector cells and of the Hela-51 cells. The Hela cells were labeled with Brdu, which detects the cells containing cells in the S phase, and with propidium iodide. Analysis by flow cytometry was carried out on the Brdu labeling. These results show that the late S-phase cells represent a small percentage of the cells in the G2/M phase for the two cell types, namely Hela-vector or Hela-51.

[0110] E. Cdc2 is hyperphosphorylated in the cells overexpressing TSAP6. Cell lysates were generated at the time points indicated after the release of DTB and immunolabeling analysis was carried out using an anti-cdc2 antibody in order to detect the various phosphorylated forms of cdc2. This analysis showed that, 12 hours after DTB release, the majority of cdc2 is dephosphorylated in the Hela-vector cells, indicating an active form. Surprisingly, on the other hand, cdc2 in the Hela-51 cells appears to be hyperphosphorylated at the same time.

[0111]FIG. 6: GST-TCTP interacts with TSAP6 in vitro

[0112] Interaction of GST-TCTP and of radiolabeled TSAP6. TSAP6 and the negative control AIP1 were generated by in vitro translation (IVT) in a rabbit reticulocyte lysate in the presence of ³⁵S-labeled methionine and ³⁵S-labeled cysteine. Equal amounts of radiolabeled products were incubated with either GST-TCTP, or GST-NKTR fusion proteins captured on the glutathione beads as a negative control. The radiolabeled proteins were eluted in a protein sample buffer, resolved under reducing conditions (0.7 mM of 2-β-mercaptoethanol) by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (10%), and visualized by autoradiography.

EXAMPLES Example 1

[0113] Binding Between TSAP6 and the Proteins Chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44 or 46, or Encoded by a Nucleic Acid Chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No.45 or 47

[0114] The binding which exists between TSAP6 and each protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, was observed in a double-hybrid system derived from the system developed by Finley and Brent (Interaction trap cloning with yeast, 169-203, in DNA Cloning, Expression Systems: a practical Approach, 1995, Oxford Universal Press, Oxford), using TSAP6 as bait and a cDNA library as prey.

[0115] The TSAP6 protein was cloned into the plasmid pEG202, known to those skilled in the art for such an application (promoter 67-1511, lexA 1538-2227, ADH Ter 2209-2522, pBR remnants 2540-2889, 2μ ori 2890-4785, YSCNFLP 4923-5729, HIS3 7190-5699, TYIB 7243-7707, RAF_part 7635-7976, backbone pBR 7995-10166, bla 8131-8988).

[0116] The cDNAs of the library are cloned into the plasmid pJG4-5, also well known to those skilled in the art (promoter GAL 1-528, fusion cassette 528-849, ADH Ter 867-1315, 2μ ori 1371-3365, TRP1 3365-4250, backbone pUC 4264-6422, Ap 4412-5274).

[0117] The reporter plasmid pSH18-34, also known to those skilled in the art, is also used. This plasmid is in particular available from Invitrogen, under the reference number V611-20, and also already transformed into the strain EGY48 (also called RFY 231), from the same supplier (reference strain alone: C835-00, transformed with pSH18-34: C836-00).

[0118] The binding was demonstrated in the yeast stain RFY 231 (described in Finley Jr. et al, 1998, Proc Natl Acad Sci USA, 95, 14266-71). This yeast strain has the genotype (MATα trp1Δ::hisG his3 ura3-1 leu2::3Lexop-LEU2), and is derived from EGY48 (Guris et al., 1993, Cell, 75, 791-803).

[0119] The reporter gene was the LacZ gene.

[0120] The study is carried out on a medium containing galactose and not containing leucine, and the presence of colored colonies is studied on these dishes.

[0121] It is thus possible to show the binding, in this system, between TSAP6 and the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44 or 46, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 45 or 47.

Example 2

[0122] Protocol for the Expression of the GST Fusion Proteins

[0123] To obtain GST fusion proteins, the following protocol can be followed:

[0124] Preparation of a preculture from an isolated colony of BL21 (DE3), transformed with the plasmid pGEX-6P-1 or pGEX-P-1, in an SB medium with 100 μg/ml of ampicillin, at 37° C.

[0125] The plasmids are available from Amersham Pharmacia Biotech AB.

[0126] The proteins are the human proteins encoded by the complementary cDNAs (SEQ ID-No 1 to SEQ ID No 7).

[0127] The following day, 250 ml of SB+Amp are inoculated with 5 ml of preculture.

[0128] Growth takes place at 28° C. or 37° C., depending on the toxicity of the proteins for the host bacteria, until an optical density of between 0.5 and 0.7 is reached. 0.1 mM IPTG is added to induce the protein synthesis.

[0129] Growth takes place at 28° C. or 37° C. for 1 h or 1 h 30.

[0130] Centrifugation is carried out at 3000 rpm for 10 min (1800 g, 4° C.).

[0131] The precipitate is resuspended in 10 ml of buffer A NP40 (1% NP40; 10 mM Tris pH 7.4; 150 mM NaCi; 1 mM EDTA; 10% glycerol; 1 mM DTT; 2 μg/ml Aprotinin; 2 μg/ml Leupeptin; 2 μg/ml Pepstatin; 1 mM AEBSF).

[0132] Sonication is carried out 3 times for 15 s at power 50, on ice.

[0133] Centrifugation is carried out at 12000 rpm for 10 min (18000 g, 4° C.).

[0134] The supernatant is kept at −80° C.

Example 3

[0135] Protocol to be Followed for Binding of the Fusion Proteins to the Sepharose-glutathion Beads

[0136] 2 ml of supernatant are added to 200 μl of beads (prepared after 3 rinses in PBS, 1 rinse in the buffer A NP40, resuspension at 50% (weight by volume) in the buffer A NP40, centrifugation at 3000 rpm each time).

[0137] The Glutathione-sepharose 4B beads are available from Amersham Pharmacia Biotech AB, under the number 17.0756.01.

[0138] Gentle mixing is carried out for at least 1 hour at 4° C.

[0139] The beads are rinsed 3 times in the buffer A NP40 without protease inhibitor.

[0140] The beads are resuspended in 1 ml of buffer A NP40 with protease inhibitor.

[0141] For the analysis by SDS-PAGE electrophoresis, a 20 to 40 μl sample of the resuspended beads is taken, centrifugation is carried out for 5 min, the supernatant is discarded, the beads are resuspended in 10 μl of loading buffer X, and heating is carried out at 97° C. for 7 min. The gel is loaded and analyzed after staining with Coomassie blue, to standardize the amount of the fusion proteins to be used.

Example 4

[0142] Protocol for the in vitro Translation of Proteins

[0143] The TNT Coupled Reticulocyte Lysate System kit from Promega is used with the T7 or T3 RNA polymerases, depending on the vector used to translate and express the proteins (for example T7 for TSAP6 1, T3 for the protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48). The kit is used according to the manufacturer's instructions (Reference L4610).

[0144] The proteins incorporate S³⁵-methionine (Amersham Pharmacia).

[0145] The products obtained in vitro are analyzed by SDS-PAGE electrophoresis.

[0146] After electrophoresis, the gel is placed in fixing buffer. (5% of methanol, 15% of acetic acid, 80% of water) for half an hour and the signal is amplified by immersing the gel in the Amplify product from Amersham Pharmacia (Ref: NAMP100).

[0147] A Kodak Biomax MR film is then exposed on the dried gel for a period of time ranging from one hour to one week, and then developed.

Example 5

[0148] Protocol for Coprecipitation of the Proteins

[0149] 30 μl of the sepharose-glutathione beads coupled to the GST fusion proteins, after standardization of the amounts, are rinsed in buffer B (1% NP40, 50 mM Tris-HCL, 150 mM NaCl, 2 μl/ml leupeptin, 1% aprotinin, 1 mM ABESF). 5 to 10 μl of the in vitro translation product as obtained in example 3 are then added, depending on the amount of the product observed by autoradiography.

[0150] After contact overnight, the beads are rinsed 10 times with buffer A NP40, without antiproteases.

[0151] Analysis is carried out by SDS-PAGE and autoradiography.

[0152] It is thus possible to show the binding between the TSAP6 proteins and said protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48.

Example 6

[0153] Protocol for Screening Compounds which Interfere with the Binding Between TSAP6 and one of the Proteins from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or Encoded by a Nucleic Acid Chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48

[0154] The assays described in examples 2 to 5 are carried out, adding the compounds intended to be studied in the step of example 5, and the results obtained when the compounds are not added are compared.

Materials and Methods

[0155] Expression and Purification of the GST Fusion Proteins

[0156] A preculture of TCTP pGEX-6P-1 or of NKTR in SB+100 μg/ml ampicillin was prepared, from a single colony, overnight at 37° C.

[0157] In the morning, 250 ml of LB+Amp were inoculated with 5 ml of this preculture.

[0158] Growth is carried out at 37° C. until the OD reaches 0.5 to 1 (approximately 3 hours).

[0159] 0.1 mM of IPTG is added.

[0160] Growth is carried out for a further 1 h 30.

[0161] Centrifugation is carried out at 3000 rpm for 10 min.

[0162] The pellet is resuspended in 10 of a lysis buffer A NP40, in such a way as to avoid bubbles:

[0163] 1% NP40*

[0164] 10 mM Tris pH 7.4*

[0165] 150 mM NaCl*

[0166] 1 mM EDTA*

[0167] 10% glycerol*

[0168] 1 mM DTT

[0169] 2 μg/ml Aprotinin

[0170] 2 μg/ml Leupeptin

[0171] 2 μg/ml Pepstatin

[0172] 1 mM AEBSF.

[0173] Sonication is carried out 3 times for 15 seconds in ice, every 15 seconds, at power 40.

[0174] Centrifugation is carried out at 12000 rpm=18000 g (1510R centrifuge) at 40° C. for 30 min.

[0175] The supernatant is conserved with care at −80° C. if necessary.

[0176] Binding to the Agarose-glutathione Beads

[0177] 2 ml of supernatant are added to 200 μl of beads (they should be prepared with 3 rinses with PBS, 1 rinse with the NP40 buffer and protease inhibitors, resuspended at 50% in this NP40 buffer, with centrifugation at 1500 rpm=900 g (1510R centrifuge) at 4° C., each time)

[0178] Gentle agitation is carried out for at least 1 hour at 4° C.

[0179] The beads are rinsed 3 times in buffer A NP40 without protease inhibitor in 10 ml of NP40 buffer each time (50 volumes).

[0180] 200 μl of beads are resuspended in 200 μl of NP40 buffer with protease inhibitors, so as to obtain a 50% solution.

[0181] Analysis of the gel: 20 μl are centrifuged for 5 minutes, the supernatant is removed, the beads are resuspended in 10 μl, twice, in a sample buffer, and heating is carried out at 97° C. for 7 min. The gel is loaded in order to standardize an amount of GST fusion proteins. Novex 10% NuPAGE gels were used with MES buffer to obtain good resolution.

[0182] In vitro translation

[0183] The “TNT Coupled Reticulocyte Lysate System” kit from Promega was used with T7 polymerase. The standard protocol was followed.

[0184] The proteins were radiolabeled with ³⁵S methionine or ³⁵S methionine, cysteine from Amersham Pharmacia. Total reaction volumes 50 μl 100 μl 150 μl 200 μl Red lysate (μl) 25 50 75 100 TNT buffer (μl) 2 4 6 8 AA mix-Met or -Met and 2 4 6 8 -Cys (μl) RNAsin (μl) 1 2 3 4 T7 RNA polymerase (μl) 1 2 3 4 35S Met or 35S Met, Cys 3 5 7 9 (μl) H20 (μl) 15 32 49 66 DNA pl 0.5 μg 1 μg 1.5 μg 2 μg

[0185] The mixture was prepared in ice. The radioactivity was added at the end.

[0186] The reaction was carried out at 30° C. for 1 h 30.

[0187] During the in vitro translation, the beads were prepared: the amount of each fusion protein bound to agarose-glutathion beads was calculated. In each case, solid beads were added so as to have a total volume of 30 μl of beads per interaction, with the aim of being able to see them at the bottom of the tube. The beads were rinsed 3 times in 1 ml of buffer B: 1% NP40, 50 mM Tris-HCl, 150 mM NaCl, 2 μg/ml Leupeptin, 1% Aprotinin, 1 mM AEBSF.

[0188] An aliquot of 30 μl of beads (60 μl of a 50% solution) was placed in Eppendorf tubes. 50 μl of buffer B NP40+inhibitors was added to each tube so as to have a significant volume during the interaction. The positive and negative controls were included. It is advisable to avoid GST alone as a negative control since it is too viscous.

[0189] As soon as the in vitro translation has taken place, 3 to 30 μl of IVT (depending on the desired standardization) are added to each 30 μl of beads.

[0190] 2X SB containing 0.7 mM of beta-mercapto ethanol is added to the remainder of the IVT in order to analyze the gel. The samples are heated at 80° C. for 5 min before being loaded.

[0191] After overnight contact at 4° C. or 1 hour at ambient temperature, the beads are rinsed 10 times in buffer A or B (if considerable stringency is acceptable) (10×1.5 ml) at 4° C. After rinsing, the beads are covered with 10 ml of buffer to which are added 30 μl of 2 times SB containing 0.7 mM of beta-mercapto ethanol and heated at 80° C. for 5 min before the analysis by SDS-PAGE. 12 to 20 μl of the samples can be loaded into each well. After electrophoresis, the gel is soaked in a fixing buffer (5% of methanol, 15% of acetic acid, 80% of water) for 30 min and the signal is amplified by immersing the gel in the Amplify product from Amersham Pharmacia.

[0192] A Kodak Biomax MR film is then exposed on the dry gel for 1 hour to 1 week and developed.

1 52 1 141 PRT Mus musculus Mouse Nix-AF067395 1 Met Ser His Val His Asn Asn Asn Asn Asn Cys Gly Ala Gly Asn Ser 1 5 10 15 Ser Trp Val Met Asn Ser Ser Asn Gly Asn Asn Gly Asn Gly Lys Asn 20 25 30 Gly Gly His Val Ser Ser Ser Ser His Asn Gly Asp Met Lys Asp Ala 35 40 45 His Ser Gly Ser Ser Ser Arg Gly Ser Ser His Cys Asp Ser Ser Asp 50 55 60 Gly Met Asp Val Met His Thr Ser Arg Asp His Ser Ser Ser Val Val 65 70 75 80 Gly Lys Val Ala Lys Lys Ser Ala Asp Trp Val Ser Asp Trp Ser Ser 85 90 95 Arg Asn Lys His Arg His Lys Arg Ala Ala Ser Ser Met Arg Lys Ser 100 105 110 Gly Ala Met Lys Lys Gly Gly Ser Ala Lys Val Ser Ser His Val Ala 115 120 125 Gly Gly Tyr Gly Lys Arg Ser Thr Ser Ala Ser Thr Tyr 130 135 140 2 219 PRT Homo sapiens Human Nix-4138826 2 Met Ser Ser His Leu Val Glu Pro Pro Pro Pro Leu His Asn Asn Asn 1 5 10 15 Asn Asn Cys Glu Glu Asn Glu Gln Ser Leu Pro Pro Pro Ala Gly Leu 20 25 30 Asn Ser Ser Trp Val Glu Leu Pro Met Asn Ser Ser Asn Gly Asn Asp 35 40 45 Asn Gly Asn Gly Lys Asn Gly Gly Leu Glu His Val Pro Ser Ser Ser 50 55 60 Ser Ile His Asn Gly Asp Met Glu Lys Ile Leu Leu Asp Ala Gln His 65 70 75 80 Glu Ser Gly Gln Ser Ser Ser Arg Gly Ser Ser His Cys Asp Ser Pro 85 90 95 Ser Pro Gln Glu Asp Gly Gln Ile Met Phe Asp Val Glu Met His Thr 100 105 110 Ser Arg Asp His Ser Ser Gln Ser Glu Glu Glu Val Val Glu Gly Glu 115 120 125 Lys Glu Val Glu Ala Leu Lys Lys Ser Ala Asp Trp Val Ser Asp Trp 130 135 140 Ser Ser Arg Pro Glu Asn Ile Pro Pro Lys Glu Phe His Phe Arg His 145 150 155 160 Pro Lys Arg Ser Val Ser Leu Ser Met Arg Lys Ser Gly Ala Met Lys 165 170 175 Lys Gly Gly Ile Phe Ser Ala Glu Phe Leu Lys Val Phe Ile Pro Ser 180 185 190 Leu Phe Leu Ser His Val Leu Ala Leu Gly Leu Gly Ile Tyr Ile Gly 195 200 205 Lys Arg Leu Ser Thr Pro Ser Ala Ser Thr Tyr 210 215 3 206 PRT Mus musculus Mouse Nix y2H 3 Asn Asn Asn Asn Asn Cys Glu Glu Gly Glu Gln Pro Leu Pro Pro Pro 1 5 10 15 Ala Gly Leu Asn Ser Ser Trp Val Glu Leu Pro Met Asn Ser Ser Asn 20 25 30 Gly Asn Glu Asn Gly Asn Gly Lys Asn Gly Gly Leu Glu His Val Pro 35 40 45 Ser Ser Ser Ser Ile His Asn Gly Asp Met Glu Lys Ile Leu Leu Asp 50 55 60 Ala Gln His Glu Ser Gly Gln Ser Ser Ser Arg Gly Ser Ser His Cys 65 70 75 80 Asp Ser Pro Ser Pro Gln Glu Asp Gly Gln Ile Met Phe Asp Val Glu 85 90 95 Met His Thr Ser Arg Asp His Ser Ser Gln Ser Glu Glu Glu Val Val 100 105 110 Glu Gly Glu Lys Glu Val Glu Ala Leu Lys Lys Ser Ala Asp Trp Val 115 120 125 Ser Asp Trp Ser Ser Arg Pro Glu Asn Ile Pro Pro Lys Glu Phe His 130 135 140 Phe Arg His Pro Lys Arg Ala Ala Ser Leu Ser Met Arg Lys Ser Gly 145 150 155 160 Ala Met Lys Lys Gly Gly Ile Phe Ser Ala Glu Phe Leu Lys Val Phe 165 170 175 Ile Pro Ser Leu Phe Leu Ser His Val Leu Ala Leu Gly Leu Gly Ile 180 185 190 Tyr Ile Gly Lys Arg Leu Ser Thr Pro Ser Ala Ser Thr Tyr 195 200 205 4 175 PRT Mus musculus Mouse Siva-AF033112 4 Met Pro Lys Arg Ser Cys Pro Phe Ala Asp Ala Ala Pro Leu Gln Leu 1 5 10 15 Lys Val His Val Gly Leu Lys Glu Leu Ser His Gly Val Phe Ala Glu 20 25 30 Arg Tyr Ser Arg Glu Val Phe Glu Arg Thr Lys Gln Leu Leu Phe Gln 35 40 45 Gly Ala Arg Ala Tyr Arg Asp His Ile Ser Ser Glu Asp Cys Ser Val 50 55 60 Asn His Leu Gln Glu Ser Leu Lys Ser Gly Val Val Gly Ala Pro Gln 65 70 75 80 Pro Ala Arg Gly Gln Met Leu Ile Gly Pro Asp Gly Arg Leu Thr Arg 85 90 95 Cys Gln Ala Gln Ala Ser Glu Gly Gly Leu Pro Arg Thr Ala Pro Ile 100 105 110 Ala Cys Ser Ser Cys Met Arg Ser Val Asp Gly Lys Ala Val Cys Ser 115 120 125 Gln Cys Glu Arg Ala Leu Cys Gly Gln Cys Val Tyr Thr Ser Trp Gly 130 135 140 Cys Gly Ala Leu Ala Cys Val Leu Cys Gly Leu Ala Asp Tyr Ala Asp 145 150 155 160 Asp Gly Glu Lys Thr Leu Cys Thr Ser Cys Ala Met Phe Glu Ala 165 170 175 5 124 PRT Homo sapiens Human Siva-HSU82938 5 Met Arg Arg Pro Gly Ser Cys Val Ala Pro Gly Pro Ala Ala Met Pro 1 5 10 15 Lys Arg Ser Cys Pro Phe Ala Asp Val Ala Pro Leu Gln Leu Lys Val 20 25 30 Arg Val Ser Gln Arg Glu Leu Ser Arg Gly Val Cys Ala Glu Arg Tyr 35 40 45 Ser Gln Glu Val Phe Asp Pro Ser Gly Val Ala Ser Ile Ala Cys Ser 50 55 60 Ser Cys Val Arg Ala Val Asp Gly Lys Ala Val Cys Gly Gln Cys Glu 65 70 75 80 Arg Ala Leu Cys Gly Gln Cys Val Arg Thr Cys Trp Gly Cys Gly Ser 85 90 95 Val Ala Cys Thr Leu Cys Gly Leu Val Asp Cys Ser Asp Met Tyr Glu 100 105 110 Lys Val Leu Cys Thr Ser Cys Ala Met Phe Glu Thr 115 120 6 197 PRT Mus musculus Mouse Siva y2H 6 Phe Gly Ser Glu Ala Lys Asn Ser Ala Arg Gly Leu Gly Ala Arg Arg 1 5 10 15 Ala Ala Arg Pro Ala Thr Met Pro Lys Arg Ser Cys Pro Phe Ala Asp 20 25 30 Ala Ala Pro Leu Gln Leu Lys Val His Val Gly Leu Lys Glu Leu Ser 35 40 45 His Gly Val Phe Ala Glu Arg Tyr Ser Arg Glu Val Phe Glu Arg Thr 50 55 60 Lys Gln Leu Leu Phe Gln Gly Ala Arg Ala Tyr Arg Asp His Ile Ser 65 70 75 80 Ser Glu Asp Cys Ser Val Asn His Leu Gln Glu Ser Leu Lys Ser Gly 85 90 95 Val Val Gly Ala Pro Gln Pro Ala Arg Gly Gln Met Leu Ile Gly Pro 100 105 110 Asp Gly Arg Leu Thr Arg Cys Gln Ala Gln Ala Ser Glu Gly Gly Leu 115 120 125 Pro Arg Thr Ala Pro Ile Ala Cys Ser Ser Cys Met Arg Ser Val Asp 130 135 140 Gly Lys Ala Val Cys Ser Gln Cys Glu Arg Ala Leu Cys Gly Gln Cys 145 150 155 160 Val Tyr Thr Ser Trp Gly Cys Gly Ala Leu Ala Cys Val Leu Cys Gly 165 170 175 Leu Ala Asp Tyr Ala Asp Asp Gly Glu Lys Thr Leu Cys Thr Ser Cys 180 185 190 Ala Met Phe Glu Ala 195 7 490 PRT Mus musculus Mouse Mytl kinase-AF175892 7 Met Thr Met Pro Thr Glu Gly Thr Pro Pro Pro Leu Ser Gly Thr Pro 1 5 10 15 Ile Pro Val Pro Ala Tyr Phe Arg His Ala Glu Pro Gly Phe Ser Leu 20 25 30 Lys Arg Pro Gly Gly Leu Ser Arg Ser Leu Pro Pro Arg Pro Pro Ala 35 40 45 Lys Gly Cys Ile Pro Val Ser Arg Leu Phe Pro Pro Arg Thr Pro Gly 50 55 60 Trp His Gln Pro Gln Pro Arg Arg Val Ser Phe Leu Cys Glu Thr Ser 65 70 75 80 Glu Pro Leu Gln Ser Pro Gly Tyr Asp Pro Ser Arg Pro Glu Ser Phe 85 90 95 Phe Gln Gln Asn Phe Gln Arg Leu Ser Arg Leu Gly His Gly Ser Tyr 100 105 110 Gly Glu Val Phe Lys Val Arg Ser Lys Glu Asp Gly Arg Leu Tyr Ala 115 120 125 Val Lys Arg Tyr Met Ser Pro Phe Arg Gly Pro Lys Asp Arg Thr Arg 130 135 140 Lys Leu Ala Glu Val Gly Gly His Glu Lys Val Gly Gln His Pro His 145 150 155 160 Cys Val Arg Leu Glu Arg Ala Trp Glu Glu Gly Gly Ile Leu Tyr Leu 165 170 175 Gln Thr Glu Leu Cys Gly Pro Ser Leu Gln Gln His Cys Glu Ala Trp 180 185 190 Gly Ala Ser Leu Pro Glu Ala Gln Val Trp Gly Tyr Leu Arg Asp Ile 195 200 205 Leu Leu Ala Leu Asp His Leu His Ser Gln Gly Leu Val His Leu Asp 210 215 220 Val Lys Pro Ala Asn Ile Phe Leu Gly Pro Arg Gly Arg Cys Lys Leu 225 230 235 240 Gly Asp Phe Gly Leu Leu Val Glu Leu Gly Ser Thr Gly Ala Gly Glu 245 250 255 Ala Gln Glu Gly Asp Pro Arg Tyr Met Ala Pro Glu Leu Leu Gln Gly 260 265 270 Ser Tyr Gly Thr Ala Ala Asp Val Phe Ser Leu Gly Leu Thr Ile Leu 275 280 285 Glu Val Ala Cys Asn Met Glu Leu Pro His Gly Gly Glu Gly Trp Gln 290 295 300 Gln Leu Arg Gln Gly Tyr Leu Pro Pro Glu Phe Thr Ala Gly Leu Ser 305 310 315 320 Ser Glu Leu Arg Ser Val Leu Ala Met Met Leu Glu Pro Asp Pro Gln 325 330 335 Leu Arg Ala Thr Ala Glu Ala Leu Leu Ala Leu Pro Met Leu Arg Gln 340 345 350 Pro Arg Pro Trp Asn Val Leu Trp Tyr Met Ala Ala Glu Ala Leu Ser 355 360 365 Arg Gly Trp Ala Leu Trp Gln Ala Leu Val Thr Leu Leu Cys Trp Leu 370 375 380 Trp His Gly Leu Val His Pro Ala Ser Trp Leu Gln Pro Pro Gly Pro 385 390 395 400 Pro Ala Thr Pro Leu Gly Ser Pro Pro Cys Ser Pro Leu Met Asn Ser 405 410 415 Thr Leu Ser Ser Ser Trp Asp Asn Asp Ser Ile Gly Pro Ser Leu Ser 420 425 430 Pro Glu Thr Val Leu Ser Arg Ile Thr Arg Arg Thr Ser Thr Pro Arg 435 440 445 Gly Arg Tyr Ile Pro Arg Asp Ala Leu Asp Leu Thr Asp Val Asp Ser 450 455 460 Glu Pro Pro Arg Gly Pro Cys Pro Thr Phe Glu Pro Arg Asn Leu Leu 465 470 475 480 Ser Leu Phe Glu Asp Ser Leu Asp Pro Ala 485 490 8 499 PRT Homo sapiens Human Myt1 kinase-2914674 8 Met Leu Glu Arg Pro Pro Ala Leu Ala Met Pro Met Pro Thr Glu Gly 1 5 10 15 Thr Pro Pro Pro Leu Ser Gly Thr Pro Ile Pro Val Pro Ala Tyr Phe 20 25 30 Arg His Ala Glu Pro Gly Phe Ser Leu Lys Arg Pro Arg Gly Leu Ser 35 40 45 Arg Ser Leu Pro Pro Pro Pro Pro Ala Lys Gly Ser Ile Pro Ile Ser 50 55 60 Arg Leu Phe Pro Pro Arg Thr Pro Gly Trp His Gln Leu Gln Pro Arg 65 70 75 80 Arg Val Ser Phe Arg Gly Glu Ala Ser Glu Thr Leu Gln Ser Pro Gly 85 90 95 Tyr Asp Pro Ser Arg Pro Glu Ser Phe Phe Gln Gln Ser Phe Gln Arg 100 105 110 Leu Ser Arg Leu Gly His Gly Ser Tyr Gly Glu Val Phe Lys Val Arg 115 120 125 Ser Lys Glu Asp Gly Arg Leu Tyr Ala Val Lys Arg Ser Met Ser Pro 130 135 140 Phe Arg Gly Pro Lys Asp Arg Ala Arg Lys Leu Ala Glu Val Gly Ser 145 150 155 160 His Glu Lys Val Gly Gln His Pro Cys Cys Val Arg Leu Glu Gln Ala 165 170 175 Trp Glu Glu Gly Gly Ile Leu Tyr Leu Gln Thr Glu Leu Cys Gly Pro 180 185 190 Ser Leu Gln Gln His Cys Glu Ala Trp Gly Ala Ser Leu Pro Glu Ala 195 200 205 Gln Val Trp Gly Tyr Leu Arg Asp Thr Leu Leu Ala Leu Ala His Leu 210 215 220 His Ser Gln Gly Leu Val His Leu Asp Val Lys Pro Ala Asn Ile Phe 225 230 235 240 Leu Gly Pro Arg Gly Arg Cys Lys Leu Gly Asp Phe Gly Leu Leu Val 245 250 255 Glu Leu Gly Thr Ala Gly Ala Gly Glu Val Gln Glu Gly Asp Pro Arg 260 265 270 Tyr Met Ala Pro Glu Leu Leu Gln Gly Ser Tyr Gly Thr Ala Ala Asp 275 280 285 Val Phe Ser Leu Gly Leu Thr Ile Leu Glu Val Ala Cys Asn Met Glu 290 295 300 Leu Pro His Gly Gly Glu Gly Trp Gln Gln Leu Arg Gln Gly Tyr Leu 305 310 315 320 Pro Pro Glu Phe Thr Ala Gly Leu Ser Ser Glu Leu Arg Ser Val Leu 325 330 335 Val Met Met Leu Glu Pro Asp Pro Lys Leu Arg Ala Thr Ala Glu Ala 340 345 350 Leu Leu Ala Leu Pro Val Leu Arg Gln Pro Arg Ala Trp Gly Val Leu 355 360 365 Trp Cys Met Ala Ala Glu Ala Leu Ser Arg Gly Trp Ala Leu Trp Gln 370 375 380 Ala Leu Leu Ala Leu Leu Cys Trp Leu Trp His Gly Leu Ala His Pro 385 390 395 400 Ala Ser Trp Leu Gln Pro Leu Gly Pro Pro Ala Thr Pro Pro Gly Ser 405 410 415 Pro Pro Cys Ser Leu Leu Leu Asp Ser Ser Leu Ser Ser Asn Trp Asp 420 425 430 Asp Asp Ser Leu Gly Pro Ser Leu Ser Pro Glu Ala Val Leu Ala Arg 435 440 445 Thr Val Gly Ser Thr Ser Thr Pro Arg Ser Arg Cys Thr Pro Arg Asp 450 455 460 Ala Leu Asp Leu Ser Asp Ile Asn Ser Glu Pro Pro Arg Gly Ser Phe 465 470 475 480 Pro Ser Phe Glu Pro Arg Asn Leu Leu Ser Leu Phe Glu Asp Thr Leu 485 490 495 Asp Pro Thr 9 150 PRT Mus musculus Mouse kinase y2h 9 Ala Glu Ala Leu Leu Ala Leu Pro Met Leu Arg Gln Pro Arg Pro Trp 1 5 10 15 Asn Val Leu Trp Tyr Met Ala Ala Glu Ala Leu Ser Arg Gly Trp Ala 20 25 30 Leu Trp Gln Ala Leu Val Thr Leu Leu Cys Trp Leu Trp His Gly Leu 35 40 45 Val His Pro Ala Ser Trp Leu Gln Pro Pro Gly Pro Pro Ala Thr Pro 50 55 60 Leu Gly Ser Pro Pro Cys Ser Pro Leu Met Asn Ser Thr Leu Ser Ser 65 70 75 80 Ser Trp Asp Asn Asp Ser Ile Gly Pro Ser Leu Ser Pro Glu Thr Val 85 90 95 Leu Ser Arg Ile Thr Arg Arg Thr Ser Thr Pro Arg Gly Arg Tyr Ile 100 105 110 Pro Arg Asp Ala Leu Asp Leu Thr Asp Val Asp Ser Glu Pro Pro Arg 115 120 125 Gly Pro Cys Pro Thr Phe Glu Pro Arg Asn Leu Leu Ser Leu Phe Glu 130 135 140 Asp Ser Leu Asp Pro Ala 145 150 10 178 PRT Mus musculus Mouse Cyclin A2-X75483 10 Met Pro Gly Thr Ser Arg His Ser Gly Arg Asp Ala Gly Ser Ala Leu 1 5 10 15 Leu Ser Leu His Gln Glu Asp Gln Glu Asn Val Asn Pro Glu Lys Leu 20 25 30 Ala Pro Ala Gln Gln Pro Arg Ala Gln Ala Val Leu Lys Ala Gly Asn 35 40 45 Val Arg Gly Pro Ala Pro Gln Gln Lys Leu Lys Thr Arg Arg Val Ala 50 55 60 Pro Leu Lys Asp Leu Pro Ile Asn Asp Glu His Val Thr Ala Gly Pro 65 70 75 80 Ser Trp Lys Ala Val Ser Lys Gln Pro Ala Phe Thr Ile His Val Asp 85 90 95 Glu Ala Glu Glu Thr Gln Lys Arg Pro Ala Glu Leu Lys Glu Thr Glu 100 105 110 Cys Glu Asp Ala Leu Ala Phe Asn Ala Ala Val Ser Leu Pro Ala Ala 115 120 125 Arg Lys Pro Leu Thr Pro Leu Asp Tyr Pro Met Asp Gly Ser Phe Glu 130 135 140 Ser Pro His Ala Met Asp Met Ser Ile Val Leu Glu Asp Lys Pro Val 145 150 155 160 Asn Val Asn Glu Val Pro Asp Tyr Gln Glu Asp Ile His Thr Tyr Leu 165 170 175 Arg Glu 11 244 PRT Homo sapiens Human Cyclin A2-510604 11 Met Glu Val Lys Cys Lys Pro Lys Val Gly Tyr Met Lys Arg Gln Pro 1 5 10 15 Asp Ile Thr Asn Ser Met Arg Ala Ile Leu Val Asp Trp Leu Val Glu 20 25 30 Val Gly Glu Glu Tyr Lys Leu Gln Asn Glu Thr Leu His Leu Ala Val 35 40 45 Asn Tyr Ile Asp Arg Phe Leu Ser Ser Met Ser Val Leu Arg Gly Lys 50 55 60 Leu Gln Leu Val Gly Thr Ala Ala Met Leu Leu Ala Ser Lys Phe Glu 65 70 75 80 Glu Ile Tyr Pro Pro Glu Val Ala Glu Phe Val Tyr Ile Thr Asp Asp 85 90 95 Thr Tyr Ser Lys Lys Gln Val Leu Arg Met Glu His Leu Val Leu Lys 100 105 110 Val Leu Ala Phe Asp Leu Ala Ala Pro Thr Val Asn Gln Phe Leu Thr 115 120 125 Gln Tyr Phe Leu His Leu Gln Pro Ala Asn Cys Lys Val Glu Ser Leu 130 135 140 Ala Met Phe Leu Gly Glu Leu Ser Leu Ile Asp Ala Asp Pro Tyr Leu 145 150 155 160 Lys Tyr Leu Pro Ser Leu Ile Ala Gly Ala Ala Phe His Leu Ala Leu 165 170 175 Tyr Thr Val Thr Gly Gln Ser Trp Pro Glu Ser Leu Ala Gln Gln Thr 180 185 190 Gly Tyr Thr Leu Glu Ser Leu Lys Pro Cys Leu Val Asp Leu His Gln 195 200 205 Thr Tyr Leu Lys Pro Pro Gln His Ala Gln Gln Ser Ile Arg Glu Lys 210 215 220 Tyr Lys His Ser Lys Tyr His Ser Val Ser Leu Leu Asn Pro Pro Glu 225 230 235 240 Thr Leu Ser Val 12 75 PRT Mus musculus Mouse Cyclin A2 y2H 12 Ala Ala Phe His Leu Ala Leu Tyr Thr Val Thr Gly Gln Ser Trp Pro 1 5 10 15 Glu Ser Leu Ala Gln Gln Thr Gly Tyr Thr Leu Glu Ser Leu Lys Pro 20 25 30 Cys Leu Val Asp Leu His Gln Thr Tyr Leu Lys Pro Pro Gln His Ala 35 40 45 Gln Gln Ser Ile Arg Glu Lys Tyr Lys His Ser Lys Tyr His Ser Val 50 55 60 Ser Leu Leu Asn Pro Pro Glu Thr Leu Ser Val 65 70 75 13 438 PRT Mus musculus Mouse PM-SCL-9506980 13 Met Lys Glu Thr Pro Leu Ser Asn Cys Glu Arg Arg Phe Leu Leu Arg 1 5 10 15 Ala Ile Glu Glu Lys Lys Arg Leu Asp Gly Arg Gln Thr Tyr Asp Tyr 20 25 30 Arg Asn Ile Arg Ile Ser Phe Gly Thr Asp Tyr Gly Cys Cys Ile Val 35 40 45 Glu Leu Gly Lys Thr Arg Val Leu Gly Gln Val Ser Cys Glu Leu Val 50 55 60 Ser Pro Lys Leu Asn Arg Ala Thr Glu Gly Ile Leu Phe Phe Asn Leu 65 70 75 80 Glu Leu Ser Gln Met Ala Ala Pro Ala Phe Glu Pro Gly Arg Gln Ser 85 90 95 Asp Leu Leu Val Lys Leu Asn Arg Leu Leu Glu Arg Cys Leu Arg Asn 100 105 110 Ser Lys Cys Ile Asp Thr Glu Ser Leu Cys Val Val Ala Gly Glu Lys 115 120 125 Val Trp Gln Ile Arg Val Asp Leu His Leu Leu Asn His Asp Gly Asn 130 135 140 Ile Ile Asp Ala Ala Ser Ile Ala Ala Ile Val Ala Leu Cys His Phe 145 150 155 160 Arg Arg Pro Asp Val Ser Val Gln Gly Glu Glu Val Thr Leu Tyr Thr 165 170 175 Pro Glu Glu Arg Asp Pro Val Pro Leu Ser Ile His His Met Pro Ile 180 185 190 Cys Val Ser Phe Ala Phe Phe Gln Gln Gly Thr Tyr Leu Leu Val Asp 195 200 205 Pro Asn Glu Arg Glu Glu Arg Val Met Asp Gly Leu Leu Val Ile Ala 210 215 220 Met Asn Lys His Arg Glu Ile Cys Thr Ile Gln Ser Ser Gly Gly Ile 225 230 235 240 Met Leu Leu Lys Asp Gln Val Phe Arg Cys Ser Lys Ile Ala Gly Val 245 250 255 Lys Val Ala Glu Ile Thr Glu Leu Ile Gln Lys Ala Leu Glu Asn Asp 260 265 270 Gln Arg Val Arg Lys Glu Gly Gly Lys Phe Gly Phe Ala Glu Ser Ile 275 280 285 Ala Asn Gln Arg Ile Thr Ala Phe Lys Met Glu Thr Ala Pro Ile Asp 290 295 300 Thr Ser Asn Ile Glu Glu Arg Ala Glu Glu Ile Ile Ala Glu Ala Glu 305 310 315 320 Pro Pro Pro Glu Val Val Ser Gln Pro Val Leu Trp Thr Pro Gly Thr 325 330 335 Ala Gln Ile Gly Asp Gly Ile Glu Asn Ser Trp Gly Asp Leu Glu Asp 340 345 350 Ser Glu Lys Glu Glu Glu Glu Glu Glu Gly Gly Ile Asp Glu Ala Val 355 360 365 Ile Leu Asp Asp Thr Lys Met Asp Thr Gly Glu Val Ser Asp Ile Gly 370 375 380 Ser Gln Gly Ala Pro Ile Val Leu Ser Asp Ser Glu Glu Glu Glu Met 385 390 395 400 Ile Ile Leu Glu Pro Glu Lys Asn Pro Lys Lys Ile Arg Ala Gln Thr 405 410 415 Ser Ala Asn Gln Lys Ala Pro Ser Lys Gly Gln Gly Lys Arg Lys Lys 420 425 430 Lys Lys Arg Thr Ala Asn 435 14 104 PRT Mus musculus Mouse PM-SCL y2h 14 Gly Thr Ala Gln Ile Gly Asp Gly Ile Glu Asn Ser Trp Gly Asp Leu 1 5 10 15 Glu Asp Ser Glu Lys Glu Glu Glu Glu Glu Glu Gly Gly Ile Asp Glu 20 25 30 Ala Val Ile Leu Asp Asp Thr Lys Met Asp Thr Gly Glu Val Ser Asp 35 40 45 Ile Gly Ser Gln Gly Ala Pro Ile Val Leu Ser Asp Ser Glu Glu Glu 50 55 60 Glu Met Ile Ile Leu Glu Pro Glu Lys Asn Pro Lys Lys Ile Arg Ala 65 70 75 80 Gln Thr Ser Ala Asn Gln Lys Ala Pro Ser Lys Gly Gln Gly Lys Arg 85 90 95 Lys Lys Lys Lys Arg Thr Ala Asn 100 15 255 PRT Mus musculus Mouse C8 proteasome-NM_011181 15 Met Ser Ser Ile Gly Thr Gly Tyr Asp Leu Ser Ala Ser Thr Phe Ser 1 5 10 15 Pro Asp Gly Arg Val Phe Gln Val Glu Tyr Ala Met Lys Ala Val Glu 20 25 30 Asn Ser Ser Thr Ala Ile Gly Ile Arg Cys Lys Asp Gly Val Val Phe 35 40 45 Gly Val Glu Lys Leu Val Leu Ser Lys Leu Tyr Glu Glu Gly Ser Asn 50 55 60 Lys Arg Leu Phe Asn Val Asp Arg His Val Gly Met Ala Val Ala Gly 65 70 75 80 Leu Leu Ala Asp Ala Arg Ser Leu Ala Asp Ile Ala Arg Glu Glu Ala 85 90 95 Ser Asn Phe Arg Ser Asn Phe Gly Tyr Asn Ile Pro Leu Lys His Leu 100 105 110 Ala Asp Arg Val Ala Met Tyr Val His Ala Tyr Thr Leu Tyr Ser Ala 115 120 125 Val Arg Pro Phe Gly Cys Ser Phe Met Leu Gly Ser Tyr Ser Ala Asn 130 135 140 Asp Gly Ala Gln Leu Tyr Met Ile Asp Pro Ser Gly Val Ser Tyr Gly 145 150 155 160 Tyr Trp Gly Cys Ala Ile Gly Lys Ala Arg Gln Ala Ala Lys Thr Glu 165 170 175 Ile Glu Lys Leu Gln Met Lys Glu Met Thr Cys Arg Asp Val Val Lys 180 185 190 Glu Val Ala Lys Ile Ile Tyr Ile Val His Asp Glu Val Lys Asp Lys 195 200 205 Ala Phe Glu Leu Glu Leu Ser Trp Val Gly Glu Leu Thr Lys Gly Arg 210 215 220 His Glu Ile Val Pro Lys Asp Ile Arg Glu Glu Ala Glu Lys Tyr Ala 225 230 235 240 Lys Glu Ser Leu Lys Glu Glu Asp Glu Ser Asp Asp Asp Asn Met 245 250 255 16 251 PRT Mus musculus Mouse C8 proteasome 16 Gly Thr Gly Tyr Asp Leu Ser Ala Ser Thr Phe Ser Pro Asp Gly Arg 1 5 10 15 Val Phe Gln Val Glu Tyr Ala Met Lys Ala Val Glu Asn Ser Ser Thr 20 25 30 Ala Ile Gly Ile Arg Cys Lys Asp Gly Val Val Phe Gly Val Glu Lys 35 40 45 Leu Val Leu Ser Lys Leu Tyr Glu Glu Gly Ser Asn Lys Arg Leu Phe 50 55 60 Asn Val Asp Arg His Val Gly Met Ala Val Ala Gly Leu Leu Ala Asp 65 70 75 80 Ala Arg Ser Leu Ala Asp Ile Ala Arg Glu Glu Ala Ser Asn Phe Arg 85 90 95 Ser Asn Phe Gly Tyr Asn Ile Pro Leu Lys His Leu Ala Asp Arg Val 100 105 110 Ala Met Tyr Val His Ala Tyr Thr Leu Tyr Ser Ala Val Arg Pro Phe 115 120 125 Gly Cys Ser Phe Met Leu Gly Ser Tyr Ser Ala Asn Asp Gly Ala Gln 130 135 140 Leu Tyr Met Ile Asp Pro Ser Gly Val Ser Tyr Gly Tyr Trp Gly Cys 145 150 155 160 Ala Ile Gly Lys Ala Arg Gln Ala Ala Lys Thr Glu Ile Glu Lys Leu 165 170 175 Gln Met Lys Glu Met Thr Cys Arg Asp Val Val Lys Glu Val Ala Lys 180 185 190 Ile Ile Tyr Ile Val His Asp Glu Val Lys Asp Lys Ala Phe Glu Leu 195 200 205 Glu Leu Ser Trp Val Gly Glu Leu Thr Lys Gly Arg His Glu Ile Val 210 215 220 Pro Lys Asp Ile Arg Glu Glu Ala Glu Lys Tyr Ala Lys Glu Ser Leu 225 230 235 240 Lys Glu Glu Asp Glu Ser Asp Asp Asp Asn Met 245 250 17 1071 PRT Homo sapiens Human CRM1-2626839 17 Met Pro Ala Ile Met Thr Met Leu Ala Asp His Ala Ala Arg Gln Leu 1 5 10 15 Leu Asp Phe Ser Gln Lys Leu Asp Ile Asn Leu Leu Asp Asn Val Val 20 25 30 Asn Cys Leu Tyr His Gly Glu Gly Ala Gln Gln Arg Met Ala Gln Glu 35 40 45 Val Leu Thr His Leu Lys Glu His Pro Asp Ala Trp Thr Arg Val Asp 50 55 60 Thr Ile Leu Glu Phe Ser Gln Asn Met Asn Thr Lys Tyr Tyr Gly Leu 65 70 75 80 Gln Ile Leu Glu Asn Val Ile Lys Thr Arg Trp Lys Ile Leu Pro Arg 85 90 95 Asn Gln Cys Glu Gly Ile Lys Lys Tyr Val Val Gly Leu Ile Ile Lys 100 105 110 Thr Ser Ser Asp Pro Thr Cys Val Glu Lys Glu Lys Val Tyr Ile Gly 115 120 125 Lys Leu Asn Met Ile Leu Val Gln Ile Leu Lys Gln Glu Trp Pro Lys 130 135 140 His Trp Pro Thr Phe Ile Ser Asp Ile Val Gly Ala Ser Arg Thr Ser 145 150 155 160 Glu Ser Leu Cys Gln Asn Asn Met Val Ile Leu Lys Leu Leu Ser Glu 165 170 175 Glu Val Phe Asp Phe Ser Ser Gly Gln Ile Thr Gln Val Lys Ser Lys 180 185 190 His Leu Lys Asp Ser Met Cys Asn Glu Phe Ser Gln Ile Phe Gln Leu 195 200 205 Cys Gln Phe Val Met Glu Asn Ser Gln Asn Ala Pro Leu Val His Ala 210 215 220 Thr Leu Glu Thr Leu Leu Arg Phe Leu Asn Trp Ile Pro Leu Gly Tyr 225 230 235 240 Ile Phe Glu Thr Lys Leu Ile Ser Thr Leu Ile Tyr Lys Phe Leu Asn 245 250 255 Val Pro Met Phe Arg Asn Val Ser Leu Lys Cys Leu Thr Glu Ile Ala 260 265 270 Gly Val Ser Val Ser Gln Tyr Glu Glu Gln Phe Val Thr Leu Phe Thr 275 280 285 Leu Thr Met Met Gln Leu Lys Gln Met Leu Pro Leu Asn Thr Asn Ile 290 295 300 Arg Leu Ala Tyr Ser Asn Gly Lys Asp Asp Glu Gln Asn Phe Ile Gln 305 310 315 320 Asn Leu Ser Leu Phe Leu Cys Thr Phe Leu Lys Glu His Asp Gln Leu 325 330 335 Ile Glu Lys Arg Leu Asn Leu Arg Glu Thr Leu Met Glu Ala Leu His 340 345 350 Tyr Met Leu Leu Val Ser Glu Val Glu Glu Thr Glu Ile Phe Lys Ile 355 360 365 Cys Leu Glu Tyr Trp Asn His Leu Ala Ala Glu Leu Tyr Arg Glu Ser 370 375 380 Pro Phe Ser Thr Ser Ala Ser Pro Leu Leu Ser Gly Ser Gln His Phe 385 390 395 400 Asp Val Pro Pro Arg Arg Gln Leu Tyr Leu Pro Met Leu Phe Lys Val 405 410 415 Arg Leu Leu Met Val Ser Arg Met Ala Lys Pro Glu Glu Val Leu Val 420 425 430 Val Glu Asn Asp Gln Gly Glu Val Val Arg Glu Phe Met Lys Asp Thr 435 440 445 Asp Ser Ile Asn Leu Tyr Lys Asn Met Arg Glu Thr Leu Val Tyr Leu 450 455 460 Thr His Leu Asp Tyr Val Asp Thr Glu Arg Ile Met Thr Glu Lys Leu 465 470 475 480 His Asn Gln Val Asn Gly Thr Glu Trp Ser Trp Lys Asn Leu Asn Thr 485 490 495 Leu Cys Trp Ala Ile Gly Ser Ile Ser Gly Ala Met His Glu Glu Asp 500 505 510 Glu Lys Arg Phe Leu Val Thr Val Ile Lys Asp Leu Leu Gly Leu Cys 515 520 525 Glu Gln Lys Arg Gly Lys Asp Asn Lys Ala Ile Ile Ala Ser Asn Ile 530 535 540 Met Tyr Ile Val Gly Gln Tyr Pro Arg Phe Leu Arg Ala His Trp Lys 545 550 555 560 Phe Leu Lys Thr Val Val Asn Lys Leu Phe Glu Phe Met His Glu Thr 565 570 575 His Asp Gly Val Gln Asp Met Ala Cys Asp Thr Phe Ile Lys Ile Ala 580 585 590 Gln Lys Cys Arg Arg His Phe Val Gln Val Gln Val Gly Glu Val Met 595 600 605 Pro Phe Ile Asp Glu Ile Leu Asn Asn Ile Asn Thr Ile Ile Cys Asp 610 615 620 Leu Gln Pro Gln Gln Val His Thr Phe Tyr Glu Ala Val Gly Tyr Met 625 630 635 640 Ile Gly Ala Gln Thr Asp Gln Thr Val Gln Glu His Leu Ile Glu Lys 645 650 655 Tyr Met Leu Leu Pro Asn Gln Val Trp Asp Ser Ile Ile Gln Gln Ala 660 665 670 Thr Lys Asn Val Asp Ile Leu Lys Asp Pro Glu Thr Val Lys Gln Leu 675 680 685 Gly Ser Ile Leu Lys Thr Asn Val Arg Ala Cys Lys Ala Val Gly His 690 695 700 Pro Phe Val Ile Gln Leu Gly Arg Ile Tyr Leu Asp Met Leu Asn Val 705 710 715 720 Tyr Lys Cys Leu Ser Glu Asn Ile Ser Ala Ala Ile Gln Ala Asn Gly 725 730 735 Glu Met Val Thr Lys Gln Pro Leu Ile Arg Ser Met Arg Thr Val Lys 740 745 750 Arg Glu Thr Leu Lys Leu Ile Ser Gly Trp Val Ser Arg Ser Asn Asp 755 760 765 Pro Gln Met Val Ala Glu Asn Phe Val Pro Pro Leu Leu Asp Ala Val 770 775 780 Leu Ile Asp Tyr Gln Arg Asn Val Pro Ala Ala Arg Glu Pro Glu Val 785 790 795 800 Leu Ser Thr Met Ala Ile Ile Val Asn Lys Leu Gly Gly His Ile Thr 805 810 815 Ala Glu Ile Pro Gln Ile Phe Asp Ala Val Phe Glu Cys Thr Leu Asn 820 825 830 Met Ile Asn Lys Asp Phe Glu Glu Tyr Pro Glu His Arg Thr Asn Phe 835 840 845 Phe Leu Leu Leu Gln Ala Val Asn Ser His Cys Phe Pro Ala Phe Leu 850 855 860 Ala Ile Pro Pro Thr Gln Phe Lys Leu Val Leu Asp Ser Ile Ile Trp 865 870 875 880 Ala Phe Lys His Thr Met Arg Asn Val Ala Asp Thr Gly Leu Gln Ile 885 890 895 Leu Phe Thr Leu Leu Gln Asn Val Ala Gln Glu Glu Ala Ala Ala Gln 900 905 910 Ser Phe Tyr Gln Thr Tyr Phe Cys Asp Ile Leu Gln His Ile Phe Ser 915 920 925 Val Val Thr Asp Thr Ser His Thr Ala Gly Leu Thr Met His Ala Ser 930 935 940 Ile Leu Ala Tyr Met Phe Asn Leu Val Glu Glu Gly Lys Ile Ser Thr 945 950 955 960 Ser Leu Asn Pro Gly Asn Pro Val Asn Asn Gln Ile Phe Leu Gln Glu 965 970 975 Tyr Val Ala Asn Leu Leu Lys Ser Ala Phe Pro His Leu Gln Asp Ala 980 985 990 Gln Val Lys Leu Phe Val Thr Gly Leu Phe Ser Leu Asn Gln Asp Ile 995 1000 1005 Pro Ala Phe Lys Glu His Leu Arg Asp Phe Leu Val Gln Ile Lys Glu 1010 1015 1020 Phe Ala Gly Glu Asp Thr Ser Asp Leu Phe Leu Glu Glu Arg Glu Ile 1025 1030 1035 1040 Ala Leu Arg Gln Ala Asp Glu Glu Lys His Lys Arg Gln Met Ser Val 1045 1050 1055 Pro Gly Ile Phe Asn Pro His Glu Ile Pro Glu Glu Met Cys Asp 1060 1065 1070 18 236 PRT Mus musculus Mouse CRM1 y2H 18 Ala Arg Gly Gly Glu Val Met Pro Phe Ile Asp Glu Ile Leu Asn Asn 1 5 10 15 Ile Asn Thr Ile Ile Cys Asp Leu Gln Pro Gln Gln Val His Thr Phe 20 25 30 Tyr Glu Ala Val Gly Tyr Met Ile Gly Ala Gln Thr Asp Gln Thr Val 35 40 45 Gln Glu His Leu Ile Glu Lys Tyr Met Leu Leu Pro Asn Gln Val Trp 50 55 60 Asp Ser Ile Ile Gln Gln Ala Thr Lys Asn Val Asp Ile Leu Lys Asp 65 70 75 80 Pro Glu Thr Val Lys Gln Leu Gly Ser Ile Leu Lys Thr Asn Val Arg 85 90 95 Ala Cys Lys Ala Val Gly His Pro Phe Val Ile Gln Leu Gly Arg Ile 100 105 110 Tyr Leu Asp Met Leu Asn Val Tyr Lys Cys Leu Ser Glu Asn Ile Ser 115 120 125 Ala Ala Ile Gln Ala Asn Gly Glu Met Val Thr Lys Gln Pro Leu Ile 130 135 140 Arg Ser Met Arg Thr Val Lys Arg Glu Thr Leu Lys Leu Ile Ser Gly 145 150 155 160 Trp Val Ser Arg Ser Asn Asp Pro Gln Met Val Ala Glu Asn Phe Val 165 170 175 Pro Pro Leu Leu Asp Ala Val Leu Ile Asp Tyr Gln Arg Asn Val Pro 180 185 190 Ala Ala Arg Glu Pro Glu Val Leu Ser Thr Met Ala Ile Ile Val Asn 195 200 205 Lys Leu Gly Gly His Ile Thr Ala Glu Ile Pro Gln Ile Phe Asp Ala 210 215 220 Val Phe Glu Cys Thr Leu Asn Met Ile Asn Lys Asp 225 230 235 19 172 PRT Mus musculus Mouse TCTP NP_033455 19 Met Ile Ile Tyr Arg Asp Leu Ile Ser His Asp Glu Leu Phe Ser Asp 1 5 10 15 Ile Tyr Lys Ile Arg Glu Ile Ala Asp Gly Leu Cys Leu Glu Val Glu 20 25 30 Gly Lys Met Val Ser Arg Thr Glu Gly Ala Ile Asp Asp Ser Leu Ile 35 40 45 Gly Gly Asn Ala Ser Ala Glu Gly Pro Glu Gly Glu Gly Thr Glu Ser 50 55 60 Thr Val Val Thr Gly Val Asp Ile Val Met Asn His His Leu Gln Glu 65 70 75 80 Thr Ser Phe Thr Lys Glu Ala Tyr Lys Lys Tyr Ile Lys Asp Tyr Met 85 90 95 Lys Ser Leu Lys Gly Lys Leu Glu Glu Gln Lys Pro Glu Arg Val Lys 100 105 110 Pro Phe Met Thr Gly Ala Ala Glu Gln Ile Lys His Ile Leu Ala Asn 115 120 125 Phe Asn Asn Tyr Gln Phe Phe Ile Gly Glu Asn Met Asn Pro Asp Gly 130 135 140 Met Val Ala Leu Leu Asp Tyr Arg Glu Asp Gly Val Thr Pro Phe Met 145 150 155 160 Ile Phe Phe Lys Asp Gly Leu Glu Met Glu Lys Cys 165 170 20 172 PRT Homo sapiens Human TCTP- NP_003286 20 Met Ile Ile Tyr Arg Asp Leu Ile Ser His Asp Glu Leu Phe Ser Asp 1 5 10 15 Ile Tyr Lys Ile Arg Glu Ile Ala Asp Gly Leu Cys Leu Glu Val Glu 20 25 30 Gly Lys Met Val Ser Arg Thr Glu Gly Ala Ile Asp Asp Ser Leu Ile 35 40 45 Gly Gly Asn Ala Ser Ala Glu Gly Pro Glu Gly Glu Gly Thr Glu Ser 50 55 60 Thr Val Val Thr Gly Val Asp Ile Val Met Asn His His Leu Gln Glu 65 70 75 80 Thr Ser Phe Thr Lys Glu Ala Tyr Lys Lys Tyr Ile Lys Asp Tyr Met 85 90 95 Lys Ser Leu Lys Gly Lys Leu Glu Glu Gln Lys Pro Glu Arg Val Lys 100 105 110 Pro Phe Met Thr Gly Ala Ala Glu Gln Ile Lys His Ile Leu Ala Asn 115 120 125 Phe Asn Asn Tyr Gln Phe Phe Ile Gly Glu Asn Met Asn Pro Asp Gly 130 135 140 Met Val Ala Leu Leu Asp Tyr Arg Glu Asp Gly Val Thr Pro Phe Met 145 150 155 160 Ile Phe Phe Lys Asp Gly Leu Glu Met Glu Lys Cys 165 170 21 34 PRT Mus musculus Mouse TCTP y2H 21 Asn Met Asn Pro Asp Gly Met Val Ala Leu Leu Asp Tyr Arg Glu Asp 1 5 10 15 Gly Val Thr Pro Phe Met Ile Phe Phe Lys Asp Gly Leu Glu Met Glu 20 25 30 Lys Cys 22 204 PRT Mus musculus Tetraspan Net6 (SAS)- AF120265 22 Met Val Cys Gly Gly Phe Ala Cys Ser Lys Asn Cys Leu Cys Ala Leu 1 5 10 15 Asn Leu Leu Tyr Thr Leu Val Ser Leu Leu Leu Ile Gly Ile Ala Ala 20 25 30 Trp Gly Ile Gly Phe Gly Leu Ile Ser Ser Leu Arg Val Val Gly Val 35 40 45 Val Ile Ala Val Gly Ile Phe Leu Phe Leu Ile Ala Leu Val Gly Leu 50 55 60 Ile Gly Ala Val Lys His His Gln Val Leu Leu Phe Phe Tyr Met Ile 65 70 75 80 Ile Leu Leu Leu Val Phe Ile Val Gln Phe Ser Val Ser Cys Ala Cys 85 90 95 Leu Ala Leu Asn Gln Glu Gln Gln Gly Gln Leu Leu Glu Val Gly Trp 100 105 110 Asn Asn Thr Ala Ser Ala Arg Asn Asp Ile Gln Arg Asn Leu Asn Cys 115 120 125 Cys Gly Phe Arg Ser Val Asn Pro Asn Asp Thr Cys Leu Ala Ser Cys 130 135 140 Val Lys Ser Asp His Ser Cys Ser Pro Cys Ala Pro Ile Ile Gly Glu 145 150 155 160 Tyr Ala Gly Glu Val Leu Arg Phe Val Gly Gly Ile Gly Leu Phe Phe 165 170 175 Ser Phe Thr Glu Ile Leu Gly Val Trp Leu Thr Tyr Arg Tyr Arg Asn 180 185 190 Gln Lys Asp Pro Arg Ala Asn Pro Ser Ala Phe Leu 195 200 23 25 PRT Mus musculus Tetraspan Net6 (SAS)-y2H 23 Glu Ile Leu Gly Val Trp Leu Thr Tyr Arg Tyr Arg Asn Gln Lys Asp 1 5 10 15 Pro Arg Ala Asn Pro Ser Ala Phe Leu 20 25 24 103 PRT Mus musculus Mouse ATPase H+ transporting mitochondrial protein-7304906 24 Met Ala Lys Phe Ile Arg Asn Phe Ala Glu Lys Ala Pro Ser Met Val 1 5 10 15 Ala Ala Ala Val Thr Tyr Ser Lys Pro Arg Leu Ala Thr Phe Trp His 20 25 30 Tyr Ala Lys Val Glu Leu Val Pro Pro Thr Pro Ala Glu Ile Pro Thr 35 40 45 Ala Ile Gln Ser Val Lys Lys Met Ile Gln Ser Ala Lys Thr Gly Ser 50 55 60 Phe Lys His Leu Thr Val Lys Glu Ala Val Leu Asn Gly Leu Val Ala 65 70 75 80 Thr Glu Val Trp Met Trp Phe Tyr Ile Gly Glu Ile Ile Gly Lys Arg 85 90 95 Gly Ile Val Gly Tyr Asp Val 100 25 103 PRT Homo sapiens Human ATPase H+ transporting mitochondrial protein- AAD20961 25 Met Ala Gln Phe Val Arg Asn Leu Val Glu Lys Thr Pro Ala Leu Val 1 5 10 15 Asn Ala Ala Val Thr Tyr Ser Lys Pro Arg Leu Ala Thr Phe Trp Tyr 20 25 30 Tyr Ala Lys Val Glu Leu Val Pro Pro Thr Pro Ala Glu Ile Pro Arg 35 40 45 Ala Ile Gln Ser Leu Lys Lys Ile Val Asn Ser Ala Gln Thr Gly Ser 50 55 60 Phe Lys Gln Leu Thr Val Lys Glu Ala Val Leu Asn Gly Leu Val Ala 65 70 75 80 Thr Glu Val Leu Met Trp Phe Tyr Val Gly Glu Ile Ile Gly Lys Arg 85 90 95 Gly Ile Ile Gly Tyr Asp Val 100 26 61 PRT Mus musculus Mouse ATPase H+ transporting mitochondrial protein-y2H 26 Pro Ala Glu Ile Pro Thr Ala Ile Gln Ser Val Lys Lys Met Ile Gln 1 5 10 15 Ser Ala Lys Thr Gly Ser Phe Lys His Leu Thr Val Lys Glu Ala Val 20 25 30 Leu Asn Gly Leu Val Ala Thr Glu Val Trp Met Trp Phe Tyr Ile Gly 35 40 45 Glu Ile Ile Gly Lys Arg Gly Ile Val Gly Tyr Asp Val 50 55 60 27 69 PRT Mus musculus Mouse Cytochrome C Oxidase 8a (Cox8a)- 6680992 27 Met Ser Val Leu Thr Pro Leu Leu Leu Arg Ser Leu Thr Gly Ser Ala 1 5 10 15 Arg Arg Leu Met Val Pro Arg Ala Gln Val His Ser Lys Pro Ala Arg 20 25 30 Glu Gln Leu Gly Val Leu Asp Ile Thr Ile Gly Leu Thr Ser Cys Phe 35 40 45 Val Cys Cys Leu Leu Pro Ala Gly Trp Val Leu Ser His Leu Glu Ser 50 55 60 Tyr Lys Lys Arg Glu 65 28 69 PRT Homo sapiens Human Mouse Cytochrome C Oxidase 8a (Cox8a)- XP_006132 28 Met Ser Val Leu Thr Pro Leu Leu Leu Arg Gly Leu Thr Gly Ser Ala 1 5 10 15 Arg Arg Leu Pro Val Pro Arg Ala Lys Ile His Ser Leu Pro Pro Glu 20 25 30 Gly Lys Leu Gly Ile Met Glu Leu Ala Val Gly Leu Thr Ser Cys Phe 35 40 45 Val Thr Phe Leu Leu Pro Ala Gly Trp Ile Leu Ser His Leu Glu Thr 50 55 60 Tyr Arg Arg Pro Glu 65 29 53 PRT Mus musculus Mouse Cytochrome C Oxidase 8a (Cox8a)-y2H 29 Arg Arg Leu Met Val Pro Arg Ala Gln Val His Ser Lys Pro Ala Arg 1 5 10 15 Glu Gln Leu Gly Val Leu Asp Ile Thr Ile Gly Leu Thr Ser Cys Phe 20 25 30 Val Cys Cys Leu Leu Pro Ala Gly Trp Val Leu Ser His Leu Glu Ser 35 40 45 Tyr Lys Lys Arg Glu 50 30 316 PRT Mus musculus Mouse Aldehyde-ketone reductase-6753037 30 Met Ala Ser His Leu Glu Leu Asn Asn Gly Thr Lys Met Pro Thr Leu 1 5 10 15 Gly Leu Gly Thr Trp Lys Ser Pro Pro Gly Gln Val Thr Glu Ala Val 20 25 30 Lys Val Ala Ile Asp Leu Gly Tyr Arg His Ile Asp Cys Ser Gln Val 35 40 45 Tyr Gln Asn Glu Lys Glu Val Gly Val Ala Leu Gln Glu Lys Leu Lys 50 55 60 Glu Gln Val Val Lys Arg Gln Asp Leu Phe Ile Val Ser Lys Leu Trp 65 70 75 80 Cys Thr Phe His Asp Lys Ser Met Val Lys Gly Ala Phe Gln Lys Thr 85 90 95 Leu Ser Asp Leu Gln Leu Asp Tyr Leu Asp Leu Tyr Leu Ile His Trp 100 105 110 Pro Thr Gly Phe Lys Pro Gly Pro Asp Tyr Phe Pro Leu Asp Ala Ser 115 120 125 Gly Asn Val Ile Pro Ser Asp Thr Asp Phe Val Asp Thr Trp Thr Ala 130 135 140 Met Glu Gln Leu Val Asp Glu Gly Leu Val Lys Thr Ile Gly Val Ser 145 150 155 160 Asn Phe Asn Pro Leu Gln Ile Glu Arg Ile Leu Asn Lys Pro Gly Leu 165 170 175 Lys Tyr Lys Pro Ala Val Asn Gln Ile Glu Cys His Pro Tyr Leu Thr 180 185 190 Gln Glu Lys Leu Ile Glu Tyr Cys His Ser Lys Gly Ile Val Val Thr 195 200 205 Ala Tyr Ser Pro Leu Gly Ser Pro Asp Arg Pro Trp Ala Lys Pro Glu 210 215 220 Asp Pro Ser Leu Leu Glu Asp Pro Arg Ile Lys Ala Ile Ala Ala Lys 225 230 235 240 Tyr Asn Lys Thr Thr Ala Gln Val Leu Ile Arg Phe Pro Ile Gln Arg 245 250 255 Asn Leu Val Val Ile Pro Lys Ser Val Thr Pro Val Arg Ile Ala Glu 260 265 270 Asn Leu Lys Val Phe Asp Phe Glu Val Ser Ser Glu Asp Met Ala Thr 275 280 285 Leu Leu Ser Tyr Asn Arg Asn Trp Arg Val Cys Ala Leu Met Ser Cys 290 295 300 Ala Lys His Lys Asp Tyr Pro Phe His Ala Glu Val 305 310 315 31 176 PRT Mus musculus Mouse Aldehyde-ketone reductase-y2H 31 Thr Trp Thr Ala Met Glu Gln Leu Val Asp Glu Gly Leu Val Lys Thr 1 5 10 15 Ile Gly Val Ser Asn Phe Asn Pro Leu Gln Ile Glu Arg Ile Leu Asn 20 25 30 Lys Pro Gly Leu Lys Tyr Lys Pro Ala Val Asn Gln Ile Glu Cys His 35 40 45 Pro Tyr Leu Thr Gln Glu Lys Leu Ile Glu Tyr Cys His Ser Lys Gly 50 55 60 Ile Val Val Thr Ala Tyr Ser Pro Leu Gly Ser Pro Asp Arg Pro Trp 65 70 75 80 Ala Lys Pro Glu Asp Pro Ser Leu Leu Glu Asp Pro Arg Ile Lys Ala 85 90 95 Ile Ala Ala Lys Tyr Asn Lys Thr Thr Ala Gln Val Leu Ile Arg Phe 100 105 110 Pro Ile Gln Arg Asn Leu Val Val Ile Pro Lys Ser Val Thr Pro Val 115 120 125 Arg Ile Ala Glu Asn Leu Lys Val Phe Asp Phe Glu Val Ser Ser Glu 130 135 140 Asp Met Ala Thr Leu Leu Ser Tyr Asn Arg Asn Trp Arg Val Cys Ala 145 150 155 160 Leu Met Ser Cys Ala Lys His Lys Asp Tyr Pro Phe His Ala Glu Val 165 170 175 32 215 PRT Mus musculus Mouse TRF-alpha (NAC)-U22151 32 Met Pro Gly Glu Ala Thr Glu Thr Val Pro Ala Thr Glu Gln Glu Leu 1 5 10 15 Pro Gln Pro Gln Ala Glu Thr Gly Ser Gly Thr Glu Ser Asp Ser Asp 20 25 30 Glu Ser Val Pro Glu Leu Glu Glu Gln Asp Ser Thr Gln Thr Ala Thr 35 40 45 Gln Gln Ala Gln Leu Ala Ala Ala Ala Glu Ile Asp Glu Glu Pro Val 50 55 60 Ser Lys Ala Lys Gln Ser Arg Ser Glu Lys Lys Ala Arg Lys Ala Met 65 70 75 80 Ser Lys Leu Gly Leu Arg Gln Val Thr Gly Val Thr Arg Val Thr Ile 85 90 95 Arg Lys Ser Lys Asn Ile Leu Phe Val Ile Thr Lys Pro Asp Val Tyr 100 105 110 Lys Ser Pro Ala Ser Asp Thr Tyr Ile Val Phe Gly Glu Ala Lys Ile 115 120 125 Glu Asp Leu Ser Gln Gln Ala Gln Leu Ala Ala Ala Glu Lys Phe Lys 130 135 140 Val Gln Gly Glu Ala Val Ser Asn Ile Gln Glu Asn Thr Gln Thr Pro 145 150 155 160 Thr Val Gln Glu Glu Ser Glu Glu Glu Glu Val Asp Glu Thr Gly Val 165 170 175 Glu Val Lys Asp Ile Glu Leu Val Met Ser Gln Ala Asn Val Ser Arg 180 185 190 Ala Lys Ala Val Arg Ala Leu Lys Asn Asn Ser Asn Asp Ile Val Asn 195 200 205 Ala Ile Met Glu Leu Thr Met 210 215 33 219 PRT Mus musculus Mouse TRF-alpha (NAC)-y2H 33 Ser Pro His Lys Met Pro Gly Glu Ala Thr Glu Thr Val Pro Ala Thr 1 5 10 15 Glu Gln Glu Leu Pro Gln Pro Gln Ala Glu Thr Gly Ser Gly Thr Glu 20 25 30 Ser Asp Ser Asp Glu Ser Val Pro Glu Leu Glu Glu Gln Asp Ser Thr 35 40 45 Gln Thr Ala Thr Gln Gln Ala Gln Leu Ala Ala Ala Ala Glu Ile Asp 50 55 60 Glu Glu Pro Val Ser Lys Ala Lys Gln Ser Arg Ser Glu Lys Lys Ala 65 70 75 80 Arg Lys Ala Met Ser Lys Leu Gly Leu Arg Gln Val Thr Gly Val Thr 85 90 95 Arg Val Thr Ile Arg Lys Ser Lys Asn Ile Leu Phe Val Ile Thr Lys 100 105 110 Pro Asp Val Tyr Lys Ser Pro Ala Ser Asp Thr Tyr Ile Val Phe Gly 115 120 125 Glu Ala Lys Ile Glu Asp Leu Ser Gln Gln Ala Gln Leu Ala Ala Ala 130 135 140 Glu Lys Phe Lys Val Gln Gly Glu Ala Val Ser Asn Ile Gln Glu Asn 145 150 155 160 Thr Gln Thr Pro Thr Val Gln Glu Glu Ser Glu Glu Glu Glu Val Asp 165 170 175 Glu Thr Gly Val Glu Val Lys Asp Ile Glu Leu Val Met Ser Gln Ala 180 185 190 Asn Val Ser Arg Ala Lys Ala Val Arg Ala Leu Lys Asn Asn Ser Asn 195 200 205 Asp Ile Val Asn Ala Ile Met Glu Leu Thr Met 210 215 34 204 PRT Mus musculus Mouse CGI-98-AF151856 34 Met Ala Lys Val Gln Val Asn Asn Val Val Val Leu Asp Asn Pro Ser 1 5 10 15 Pro Phe Tyr Asn Pro Phe Gln Phe Glu Ile Thr Phe Glu Cys Ile Glu 20 25 30 Asp Leu Ser Glu Asp Leu Glu Trp Lys Ile Ile Tyr Val Gly Ser Ala 35 40 45 Glu Ser Glu Glu Tyr Asp Gln Val Leu Asp Ser Val Leu Val Gly Pro 50 55 60 Val Pro Ala Gly Arg His Met Phe Val Phe Gln Ala Asp Ala Pro Asn 65 70 75 80 Pro Gly Leu Ile Pro Asp Ala Asp Ala Val Gly Val Thr Val Val Leu 85 90 95 Ile Thr Cys Thr Tyr Arg Gly Gln Glu Phe Ile Arg Val Gly Tyr Tyr 100 105 110 Val Asn Asn Glu Tyr Thr Glu Thr Glu Leu Arg Glu Asn Pro Pro Val 115 120 125 Lys Pro Asp Phe Ser Lys Leu Gln Arg Asn Ile Leu Ala Ser Asn Pro 130 135 140 Arg Val Thr Arg Phe His Ile Asn Trp Glu Asp Asn Thr Glu Lys Leu 145 150 155 160 Glu Asp Ala Glu Ser Ser Asn Pro Asn Leu Gln Ser Leu Leu Ser Thr 165 170 175 Asp Ala Leu Pro Ser Ala Ser Lys Gly Trp Ser Thr Ser Glu Asn Ser 180 185 190 Leu Asn Val Met Leu Glu Ser His Met Asp Cys Met 195 200 35 219 PRT Mus musculus Mouse CGI-98-y2H 35 Ser Pro His Lys Met Pro Gly Glu Ala Thr Glu Thr Val Pro Ala Thr 1 5 10 15 Glu Gln Glu Leu Pro Gln Pro Gln Ala Glu Thr Gly Ser Gly Thr Glu 20 25 30 Ser Asp Ser Asp Glu Ser Val Pro Glu Leu Glu Glu Gln Asp Ser Thr 35 40 45 Gln Thr Ala Thr Gln Gln Ala Gln Leu Ala Ala Ala Ala Glu Ile Asp 50 55 60 Glu Glu Pro Val Ser Lys Ala Lys Gln Ser Arg Ser Glu Lys Lys Ala 65 70 75 80 Arg Lys Ala Met Ser Lys Leu Gly Leu Arg Gln Val Thr Gly Val Thr 85 90 95 Arg Val Thr Ile Arg Lys Ser Lys Asn Ile Leu Phe Val Ile Thr Lys 100 105 110 Pro Asp Val Tyr Lys Ser Pro Ala Ser Asp Thr Tyr Ile Val Phe Gly 115 120 125 Glu Ala Lys Ile Glu Asp Leu Ser Gln Gln Ala Gln Leu Ala Ala Ala 130 135 140 Glu Lys Phe Lys Val Gln Gly Glu Ala Val Ser Asn Ile Gln Glu Asn 145 150 155 160 Thr Gln Thr Pro Thr Val Gln Glu Glu Ser Glu Glu Glu Glu Val Asp 165 170 175 Glu Thr Gly Val Glu Val Lys Asp Ile Glu Leu Val Met Ser Gln Ala 180 185 190 Asn Val Ser Arg Ala Lys Ala Val Arg Ala Leu Lys Asn Asn Ser Asn 195 200 205 Asp Ile Val Asn Ala Ile Met Glu Leu Thr Met 210 215 36 412 DNA Mus musculus misc_feature 26...411 n=A, C, G and T 36 ggcacgaggc ctcgtgccga attcgnnacg aggnnnngag agaactantn tcgangcatg 60 catntagagg cccgcatcat gtaattatnt tatgtcactg cttacattca cagcattgng 120 gnctttntgg ataantatcc tcccccaagt ttgggatgag actactanat gnngactggg 180 ntntgacnct tgnttaagca ctttattaag ggcattgact tgngtggtgn ngtgggtaac 240 ccccattctt ccacagcctg caagggaagg ncttccanaa aggctgtgga ctggggnttg 300 ggngagacta gccannagtg agccctgcac ancaaggtaa tgggggttgn gcanagacag 360 ncctagatct ggntttgtaa tgatttatnc nnnaaataaa nannccnnnn nc 412 37 601 DNA Mus musculus misc_feature 10...577 n=A, C, G and T 37 ggcacgaggn anagaactaa cacttagang catgcatcta gagngccgna tcntgaannt 60 attcctttgc tcacaaggtg ttgctttgtc ctcgtgatga gtttataagc cttcttccct 120 ccctgctcct taacaaaaac aatgtgatgg atcggtgatg ttcacagttc tccctgtgcg 180 gatgcacttg tgctcatagg gtttggtaag atgatctcaa gtaactacac cagctttggt 240 gtagcagtga actccgggtg gtgctgggat ctgatccaac gaaaaacact tgccattctc 300 accgaagaga actggctttg ggactctgtt aactttgggg aaggaaacat tgtatgtttg 360 gctcagtgtg cttggctggt taatctttgg taatttcacc tgaatgagat ttgatgaatt 420 aatgaatatt gaatttaaaa ctaattatga gtgaaaaata aaagggncgn gcttaaaaag 480 gtatgtcacg ctnacnttca cgcacccccg tggggcacgt tccatgtgtt cncnggccng 540 gacccaagcg tnacaggcat tacaactntg cccgagnctg agatggctct aaaaaaaaaa 600 a 601 38 256 DNA Mus musculus misc_feature 113 n=A, C, G and T 38 ggcacgaggg tagcaattga aatgagaaat cagttcatca tttcaagtac tacattgcct 60 gcattacaaa ttctctgatc acagaattgt acataaccct gagcctatgt acntgccatt 120 tgattgtcag gttccatttg tgtcaaaacc taaagatagt gatgaccaag tgaaacagag 180 tggtgtattg ctttttcata tgaatatttt cacataaaag catttgtgaa agcaaaaaaa 240 aaaaaaaaaa aaaaaa 256 39 545 DNA Mus musculus misc_feature 204...541 n=A, C, G and T 39 ggcacgaggc agtatctccc agtagcactt cttctggatt tgaattcaaa tgtcattctt 60 aacatttctg ttgatgcttc tttgaaaatc ttcgcttgat tttggctgta aatcacctac 120 cctgttaaat gcttgtttaa tcccaaggat gtaagttgag gtgaggtgtc ttctctgtct 180 gccccattgc actcaactga atanaaatat ttggntttag agcatctcaa aagtgggtag 240 aatgtccttt gggattttgt tgctccgttt aaaccaggtg tatngcgaca tgaacatgac 300 tttcctaaag tggaaggatc tgtccccacc ttcacccagt ccttangaca agtagaaagg 360 ggcancctgg cacttggcat aacctatgcc accanggcna gataactgtg aaaaagnggt 420 atcctctgat gtcccncgta ttagnctcnn nttacaaanc acttaataaa actancctac 480 tgtnnaacca ncnccaaaac cnacaaancc cccgcccctt ttttttnnan cggncccccn 540 ntaga 545 40 477 DNA Mus musculus Mouse TSAP6int.EST.Cl.23(200)same as Cl.40-AA915693 40 ccagtagcac ttcttctgga tttgaattca aatgtcattc ttaacatttc tgttgatgct 60 tctttgaaaa tcttcgcttg attttggctg taaatcacct accctgttaa atgctgttta 120 atcccaagga tgtaagttga ggtgaggtgt cttctctgtc tgccccattg cactcaactg 180 aatagaaata tttgggttta gagcatctca aaagtgggta gaatgtcctt tgggattttg 240 ttgctccgtt taaaccaggt gtattgtgac atgaacatga ctttcctaaa gtggaaggat 300 ctgtccccac cttcacccag tccttaggac aagtagaaag gggcattctg gcacttggca 360 taacctatgc cacgatggtg agataatgtg aaaaagtggt atcctctgat gtcagcgtat 420 tagtctcagt ttacaaagta cttaataaaa ctaactactg taaaaccaaa aaaaaaa 477 41 733 DNA Mus musculus Mouse TSAP6int.EST.Cl.62(342)-AA537195 41 gaattcggca cgagggtgtg cttggcctct gttagactcc tgtgtggttc cacaatgcct 60 aagaaagccg gtgcgacaag caagggtaaa aaccaaacca aagaaccaga gacagcacct 120 cctgctgcag ggcctgtagc aactgaccct aaaggttttg tcaccatagc cattcatgcc 180 aaacctggct ccagacagaa cgctgtgaca gatctgagca ctgaggccgt tggtgtggcc 240 attgcagcac ctccgtccca gggagaggca aatgcggagc tgtgtcggta cctctccaag 300 gtcttggacc tcaggaagag tgacgtggtt ctggataagg gtggtaaatc tcgggaaaag 360 gtggtgaagc tcttggcctc tacaactcca gaggaggtct tggagaagct gaaaacagaa 420 gctgagaaga aataaaggcg agaaatggaa acagctgctg tctgcgacgg agcatctgag 480 ctgcaggcac tgggagagga gctgaaggtc gccgcgtgga ggcggacagg acaccagctc 540 cctggactcc gagtgaagct ttagctttat agctccacaa tgttttgtgg agttctgggg 600 tctcctaatt cagtttacaa ctggaaaacc ttttgtgctg cttctattct aagtttttgg 660 tttttaaatg caaaagtgtt ctctttatat cttttaaaga ttctctggac atttcgtgga 720 aaagtaaata atc 733 42 611 DNA Mus musculus misc_feature 16...575 n=A, C, G and T 42 gaattcggca cgaggnntan ctctaaaanc tgatntnngn ggcactatta naagntnnac 60 tataaggagn ttctgnttgc cntgtaccta gcacttcccc agatgngcan ataacggagt 120 agncaggtgg aatgcactaa tgcacccagc attcatgtgg ggtangagga gcgggnaggt 180 caaagtggnc cttacaaata gcaggctcta ngccagggtg gnctatagat gactctgnnt 240 ctaacaaaca cacaaataaa acattgtgtg aatgatggta ttttagtaca tggttctcta 300 cccagcccct ctgtccctca ngcattctan actctgtgct gacaggacta aattgctcct 360 acaaaaataa tagtactaan gtataancca attctatatt tgtgatagaa naaaaaatga 420 atattcttta acaggaagta tgttcctaga atgggatatc atatggtaaa ttacagtgat 480 aacaatagat ctggttgaca tgacgttata tttttgtgaa gtatttcana agaatatata 540 ttttctcagt tttataaaaa tgaaaaataa aaganattgg ttgtttataa aaaaaaaaaa 600 aaanaaaaaa a 611 43 548 DNA Mus musculus misc_feature 30...85 n=A, C, G and T 43 gaattcggca cgagggagag agagaactan tctcgaggca tgcatctaga ggnccgcatc 60 atgtaattag ntatgtcacg cttcnttcac gcagtcatat ttcataagct cttttggcct 120 gggtacagca gaaaactagc agttttccta cttggcgcaa gtgacttgtg cctccttgtc 180 tgtcctttgt cagcacaggt gcaggcaaac ccttccagct gggttaattg ccgtttatgg 240 tttactcact tagggaaagg gcttaggtgt taggctgtgg gctgcttctc cctaaccatc 300 cattgtgcag acttctcatc taaaaaggtt ggtggctttt gcttgggatc agtgctctgc 360 taacgccctt gctggtctct ccacacattc ctgtcattga gacttgaatt gtaggtgtga 420 tgttatgcac aggatgctca gagctatgtt actactattc ttagtttgta aattgtcctt 480 ttgataccat cttgttttct tttgtaggta taaataaata cttgacaata aaaaaaaaaa 540 aaaaaaaa 548 44 338 PRT Mus musculus Mouse TSAP6int. HUKIAA0095-11435026 44 Met Glu Arg Leu Arg Cys His Ala Val His Val Ala Leu Val Leu Phe 1 5 10 15 Glu Leu Lys Leu Leu Leu Lys Ser Ser Gly Gln Ser Ala Gln Leu Leu 20 25 30 Ser His Glu Pro Gly Asp Pro Pro Cys Leu Arg Arg Leu Asn Phe Val 35 40 45 Arg Leu Leu Met Leu Tyr Thr Arg Lys Phe Glu Ser Thr Asp Pro Arg 50 55 60 Glu Ala Leu Gln Tyr Phe Tyr Phe Leu Arg Asp Glu Lys Asp Ser Gln 65 70 75 80 Gly Glu Asn Met Phe Leu Arg Cys Val Ser Glu Leu Val Ile Glu Ser 85 90 95 Arg Glu Phe Asp Met Ile Leu Gly Lys Leu Glu Asn Asp Gly Ser Arg 100 105 110 Lys Pro Gly Val Ile Asp Lys Phe Thr Ser Asp Thr Lys Pro Ile Ile 115 120 125 Asn Lys Val Ala Ser Val Ala Glu Asn Lys Gly Leu Phe Glu Glu Ala 130 135 140 Ala Lys Leu Tyr Asp Leu Ala Lys Asn Ala Asp Lys Val Leu Glu Leu 145 150 155 160 Met Asn Lys Leu Leu Ser Pro Val Val Pro Gln Ile Ser Ala Pro Gln 165 170 175 Ser Asn Lys Glu Arg Leu Lys Asn Met Ala Leu Ser Ile Ala Glu Arg 180 185 190 Tyr Arg Ala Gln Gly Ile Ser Ala Asn Lys Phe Val Asp Ser Thr Phe 195 200 205 Tyr Leu Leu Leu Asp Leu Ile Thr Phe Phe Asp Glu Tyr His Ser Gly 210 215 220 His Ile Asp Arg Ala Phe Asp Ile Ile Glu Arg Leu Lys Leu Val Pro 225 230 235 240 Leu Asn Gln Glu Ser Val Glu Glu Arg Val Ala Ala Phe Arg Asn Phe 245 250 255 Ser Asp Glu Ile Arg His Asn Leu Ser Glu Val Leu Leu Ala Thr Met 260 265 270 Asn Ile Leu Phe Thr Gln Phe Lys Arg Leu Lys Gly Thr Ser Pro Ser 275 280 285 Ser Ser Ser Arg Pro Gln Arg Val Ile Glu Asp Arg Asp Ser Gln Leu 290 295 300 Arg Ser Gln Ala Arg Thr Leu Ile Thr Phe Ala Gly Met Ile Pro Tyr 305 310 315 320 Arg Thr Ser Gly Asp Thr Asn Ala Arg Leu Val Gln Met Glu Val Leu 325 330 335 Met Asn 45 75 PRT Mus musculus Mouse TSAP6int. HUKIAA0095-y2H 45 Leu Ser Glu Val Leu Leu Ala Thr Met Asn Ile Leu Phe Thr Gln Phe 1 5 10 15 Lys Arg Leu Lys Gly Thr Ser Pro Ser Ser Ser Ser Arg Pro Gln Arg 20 25 30 Val Ile Glu Asp Arg Asp Ser Gln Leu Arg Ser Gln Ala Arg Thr Leu 35 40 45 Ile Thr Phe Ala Gly Met Ile Pro Tyr Arg Thr Ser Gly Asp Thr Asn 50 55 60 Ala Arg Leu Val Gln Met Glu Val Leu Met Asn 65 70 75 46 147 DNA Mus musculus Mouse Sca-1 Non-coding region NM_008529 46 gttcaggagg ctgcccatgg aggactgcca cccctccaga tgaaggctcc cactacccga 60 tgcagttgag tcccatcctg ccctctctgc ccacactggc ttcctgctgc tattctagtg 120 cctcaaataa accgttcaca cccttaa 147 47 50 PRT Mus musculus misc_feature 49 Xaa=any amino acid 47 Val Gln Glu Ala Ala His Gly Gly Leu Pro Pro Leu Gln Met Lys Ala 1 5 10 15 Pro Thr Thr Arg Cys Ser Xaa Val Pro Ser Cys Pro Leu Cys Pro His 20 25 30 Trp Leu Pro Ala Ala Ile Leu Val Pro Gln Ile Asn Arg Ser His Pro 35 40 45 Xaa Lys 50 48 133 DNA Mus musculus Mouse Nebulin related anchoring protein U76618 48 ggcacgaggc ttttggatat atttttaatt aaaaaaatca catgagaaat gtaatctgta 60 tagtgatact ttaataagca catactcaat aaacaactgc aatgatgtcg acagcaaaaa 120 aaaaaaaaaa aaa 133 49 2969 DNA Mus musculus Murine sequence TSAP6 49 cctcggaaac ttaggtgaat ccacttctag tccagacctt tgaggtggga agacacacct 60 ttaatctggg ccacaccttc tgctgggagg tataaggacg cagacctgct ctttgcctgc 120 ttgtcctcac cttgctaaca catccactcc tcactggcac tggggctact tctttgggat 180 tccagcatat actgaagacc agctgaaata tctagcctca tagactgaac aactactgga 240 tttttggact ttctgttcac agtcaggtat actgcagcct tgagctccag ccacccagct 300 tcagaagaaa tggctgcaga ggcccacagg cagcagggct cttgccccac catcccctca 360 gagggctgtg gaaagtcacc agagaagaaa ggcagtgcgg ccgactctag acctggcact 420 gctatgtcgg gggagatgga caagccgctg atcagccgcc gcctagtgga cagtgatggc 480 agtctggctg aggtccccaa ggaggccccc aaagtgggca tcctgggcag tggggatttt 540 gcccgttccc tggccacacg cctggtgggc tctggcttca gtgtggtggt ggggagccgt 600 aaccccaaac gcacggctgg cctcttcccc tccttagctc aagtgacttt ccaggaggaa 660 gccgtgagct ctccagaggt catctttgtg gccgtgttcc gggagcacta ctcctcactg 720 tgcagtcttg ctgaccagtt ggctggcaag atcctcgtgg atgtaagcaa ccccacggag 780 aaggagcatc ttcagcaccg ccagtctaat gctgagtacc tggcctcact ctttcctgcg 840 tgcactgtgg tgaaggcctt caacgtcatc tctgcatggg ccctacaggc tggcccaagg 900 gatgggaaca ggcaggtgct catctgcagt gatcagccag aagccaagcg caccatctca 960 gagatggcac gcgccatggg tttcacaccc ctggacatgg gatccctggc ctcagcgagg 1020 gaggtagaag ccatacccct gcgcctcctt ccatcctgga aggtgcccac cctcctggca 1080 ctggggctct ttgtgtgctt ctacacctac aacttcatcc gggacgttct acagccatac 1140 attcggaaag atgagaacaa gttctacaag atgcccttgt ctgtggtcaa caccacacta 1200 ccctgtgtgg cttatgtgct gctgtcccta gtgtacctgc ccggtgtgct ggcagctgcg 1260 cttcagctgc ggagggggac caagtaccag cgcttcccag actggctgga ccactggctg 1320 cagcatcgca agcagatcgg gctgctcagc ttcttcttcg cgatgctgca cgctctctac 1380 agcttctgcc tgccgctgcg ccgctcccac cgctacgacc tggtcaatct ggctgtgaag 1440 caggtcctgg ccaacaagag ccgcctctgg gttgaggaag aagtctggag gatggagata 1500 tacctgtccc tgggtgtgct ggccctgggc atgttgtcgc tgctggctgt cacctcgctc 1560 ccgtccattg ccaactccct caactggaag gagttcagct tcgtgcagtc cacgctgggc 1620 ttcgtggccc tgatactcag cacaatgcac acactcacct acggctggac ccgtgccttt 1680 gaggaaaacc actacaagtt ctacctgccg cccacattca cactcacgct gctcctgccc 1740 tgtgtgatca tcctggccaa gggcctcttc ctcctgccct gcctcagccg cagactcacc 1800 aagatccgca ggggctggga gaaagatggg gctgtcaagt tcatgctgcc cggcgaccac 1860 acacaggggg agaaaacaag ccacgtgtga ggccctggaa gcggagatgg cttgtggggg 1920 ccctgagctg ggttcgggtc tcttttctgg atgctgcaca gcgaggtgat gatatatgcg 1980 tgggtggctg agatcctaat tcctggggtg caggtgtaaa ctgacatact cagaatgaca 2040 ccccatacat gtgatatgta ctcacatata tttcacatat aataagattt gctattattc 2100 ttacttagct aaaaaaaaaa agtgggtccc tatatttcag cgtaagcatt tcaaagcaaa 2160 tgccacacat tgaacagcag atcccaccct tgtggtatct acagaggcag acagacactc 2220 tggtatagga gaaactgtct ttcgttggat tctctccttt aatctctatg ctccttatta 2280 gctgaatcct aaagttggtg caaagctggg gcaagaaatg cctctggtgc cacctacccc 2340 catcccaggg ctaagaaaga agcctcgagt gaacagggaa ccaggtctgg actctgctgc 2400 ttccctgggc gtgcgtgggg aggctcagca agaccccctg ggatctatgc aggagctttt 2460 tcaggtccgt cctttcttca gggaagggtc tgaagctgcc ccatctgatc ctagctgagc 2520 tgagaagatt cttccccacc ccctgaaagt ccagagtcac caccggagcc tgcaaattga 2580 tccttctgcg aaggtgtgaa gtcaccgcct ctccagagcc attaatgaac ctggtcttcg 2640 ggaggaggat aattgtttcc tctccattaa gttgctggtg accccccttt aaatcactgt 2700 gccttctcgc cttttccatc attaatttgg acatctccgt ggagtggaca cttgtctggg 2760 cagttcgggg ggggggggag cattagagat tgcagagaat aaccatcgaa tcctcttctt 2820 ggggcaaccc tccccttgga tgtgccccag gcctgccttc attaaattgg tccctgagga 2880 gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaattta aaaaaaaaaa 2940 aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 2969 50 526 PRT Mus musculus Murine TSAP6 protein 50 Met Ala Ala Glu Ala His Arg Gln Gln Gly Ser Cys Pro Thr Ile Pro 1 5 10 15 Ser Glu Gly Cys Gly Lys Ser Pro Glu Lys Lys Gly Ser Ala Ala Asp 20 25 30 Ser Arg Pro Gly Thr Ala Met Ser Gly Glu Met Asp Lys Pro Leu Ile 35 40 45 Ser Arg Arg Leu Val Asp Ser Asp Gly Ser Leu Ala Glu Val Pro Lys 50 55 60 Glu Ala Pro Lys Val Gly Ile Leu Gly Ser Gly Asp Phe Ala Arg Ser 65 70 75 80 Leu Ala Thr Arg Leu Val Gly Ser Gly Phe Ser Val Val Val Gly Ser 85 90 95 Arg Asn Pro Lys Arg Thr Ala Gly Leu Phe Pro Ser Leu Ala Gln Val 100 105 110 Thr Phe Gln Glu Glu Ala Val Ser Ser Pro Glu Val Ile Phe Val Ala 115 120 125 Val Phe Arg Glu His Tyr Ser Ser Leu Cys Ser Leu Ala Asp Gln Leu 130 135 140 Ala Gly Lys Ile Leu Val Asp Val Ser Asn Pro Thr Glu Lys Glu His 145 150 155 160 Leu Gln His Arg Gln Ser Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro 165 170 175 Ala Cys Thr Val Val Lys Ala Phe Asn Val Ile Ser Ala Trp Ala Leu 180 185 190 Gln Ala Gly Pro Arg Asp Gly Asn Arg Gln Val Leu Ile Cys Ser Asp 195 200 205 Gln Pro Glu Ala Lys Arg Thr Ile Ser Glu Met Ala Arg Ala Met Gly 210 215 220 Phe Thr Pro Leu Asp Met Gly Ser Leu Ala Ser Ala Arg Glu Val Glu 225 230 235 240 Ala Ile Pro Leu Arg Leu Leu Pro Ser Trp Lys Val Pro Thr Leu Leu 245 250 255 Ala Leu Gly Leu Phe Val Cys Phe Tyr Thr Tyr Asn Phe Ile Arg Asp 260 265 270 Val Leu Gln Pro Tyr Ile Arg Lys Asp Glu Asn Lys Phe Tyr Lys Met 275 280 285 Pro Leu Ser Val Val Asn Thr Thr Leu Pro Cys Val Ala Tyr Val Leu 290 295 300 Leu Ser Leu Val Tyr Leu Pro Gly Val Leu Ala Ala Ala Leu Gln Leu 305 310 315 320 Arg Arg Gly Thr Lys Tyr Gln Arg Phe Pro Asp Trp Leu Asp His Trp 325 330 335 Leu Gln His Arg Lys Gln Ile Gly Leu Leu Ser Phe Phe Phe Ala Met 340 345 350 Leu His Ala Leu Tyr Ser Phe Cys Leu Pro Leu Arg Arg Ser His Arg 355 360 365 Tyr Asp Leu Val Asn Leu Ala Val Lys Gln Val Leu Ala Asn Lys Ser 370 375 380 Arg Leu Trp Val Glu Glu Glu Val Trp Arg Met Glu Ile Tyr Leu Ser 385 390 395 400 Leu Gly Val Leu Ala Leu Gly Met Leu Ser Leu Leu Ala Val Thr Ser 405 410 415 Leu Pro Ser Ile Ala Asn Ser Leu Asn Trp Lys Glu Phe Ser Phe Val 420 425 430 Gln Ser Thr Leu Gly Phe Val Ala Leu Ile Leu Ser Thr Met His Thr 435 440 445 Leu Thr Tyr Gly Trp Thr Arg Ala Phe Glu Glu Asn His Tyr Lys Phe 450 455 460 Tyr Leu Pro Pro Thr Phe Thr Leu Thr Leu Leu Leu Pro Cys Val Ile 465 470 475 480 Ile Leu Ala Lys Gly Leu Phe Leu Leu Pro Cys Leu Ser Arg Arg Leu 485 490 495 Thr Lys Ile Arg Arg Gly Trp Glu Lys Asp Gly Ala Val Lys Phe Met 500 505 510 Leu Pro Gly Asp His Thr Gln Gly Glu Lys Thr Ser His Val 515 520 525 51 1720 DNA Homo sapiens Human sequence TSAP6 51 acccagccac caaaatgcca gaagagatgg acaagccact gatcagcctc cacctggtgg 60 acagcgatag tagccttgcc aaggtccccg atgaggcccc caaagtgggc atcctgggta 120 gcggggactt tgcccgctcc ctggccacac gcctggtggg ctctggcttc aaagtggtgg 180 tggggagccg caaccccaaa cgcacagcca ggctgtttcc ctcagcggcc caagtgactt 240 tccaagagga ggcagtgagc tccccggagg tcatctttgt ggctgtgttc cgggagcact 300 actcttcact gtgcagtctc agtgaccagc tggcgggcaa gatcctggtg gatgtgagca 360 accctacaga gcaagagcac cttcagcatc gtgagtccaa tgctgagtac ctggcctccc 420 tcttccccac ttgcacagtg gtcaaggcct tcaatgtcat ctctgcctgg accctgcagg 480 ctggcccaag ggatggtaac aggcaggtgc ccatctgcgg tgaccagcca gaagccaagc 540 gtgctgtctc ggagatggcg ctcgccatgg gcttcatgcc cgtggacatg ggatccctgg 600 cgtcagcctg ggaggtggag gccatgcccc tgcgcctcct cccggcctgg aaggtgccca 660 ccctgctggc cctggggctc ttcgtctgct tctatgccta caacttcgtc cgggacgttc 720 tgcagcccta tgtgcaggaa agccagaaca agttcttcaa gctgcccgtg tccgtggtca 780 acaccacact gccgtgcgtg gcctacgtgc tgctgtcact cgtgtacttg cccggcgtgc 840 tggcggctgc cctgcagctg cggcgcggca ccaagtacca gcgcttcccc gactggctgg 900 accactggct acagcaccgc aagcagatcg ggctgctcag cttcttctgc gccgccctgc 960 acgccctcta cagcttctgc ttgccgctgc gccgcgccca ccgctacgac ctggtcaacc 1020 tggcagtcaa gcaggtcttg gccaacaaga gccacctctg ggtggaggag gaggtctggc 1080 ggatggagat ctacctctcc ctgggagtgc tggccctcgg cacgttgtcc ctgctggccg 1140 tgacctcact gccgtccatt gcaaactcgc tcaactggag ggagttcagc ttcgttcagt 1200 cctcactggg ctttgtggcc ctcgtgctga gcacactgca cacgctcacc tacggctgga 1260 cccgcgcctt cgaggagagc cgctacaagt tctacctgcc tcccaccttc acgctcacgc 1320 tgctggtgcc ctgcgtcgtc atcctggcca aagccctgtt tctcctgccc tgcatcagcc 1380 gcagactcgc caggatccgg agaggctggg agagggagag caccatcaag ttcacgctgc 1440 ccacagacca cgccctggcc gagaagacga gccacgtatg aggtgcctgc cctgggctct 1500 ggaccccggg cacacgaggg acggtgccct gagcccgtta ggttttcttt tcttggtggt 1560 gcaaagtggt ataactgtgt gcaaatagga ggtttgaggt ccaaattcct gggactcaaa 1620 tgtatgcagt actattcaga atgatataca cacatatgtg tatatgtatt tacatatatt 1680 ccacatatat aacaggattt gcaattatac atagctagct 1720 52 488 PRT Homo sapiens Human TSAP6 protein 52 Met Pro Glu Glu Met Asp Lys Pro Leu Ile Ser Leu His Leu Val Asp 1 5 10 15 Ser Asp Ser Ser Leu Ala Lys Val Pro Asp Glu Ala Pro Lys Val Gly 20 25 30 Ile Leu Gly Ser Gly Asp Phe Ala Arg Ser Leu Ala Thr Arg Leu Val 35 40 45 Gly Ser Gly Phe Lys Val Val Val Gly Ser Arg Asn Pro Lys Arg Thr 50 55 60 Ala Arg Leu Phe Pro Ser Ala Ala Gln Val Thr Phe Gln Glu Glu Ala 65 70 75 80 Val Ser Ser Pro Glu Val Ile Phe Val Ala Val Phe Arg Glu His Tyr 85 90 95 Ser Ser Leu Cys Ser Leu Ser Asp Gln Leu Ala Gly Lys Ile Leu Val 100 105 110 Asp Val Ser Asn Pro Thr Glu Gln Glu His Leu Gln His Arg Glu Ser 115 120 125 Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Thr Cys Thr Val Val Lys 130 135 140 Ala Phe Asn Val Ile Ser Ala Trp Thr Leu Gln Ala Gly Pro Arg Asp 145 150 155 160 Gly Asn Arg Gln Val Pro Ile Cys Gly Asp Gln Pro Glu Ala Lys Arg 165 170 175 Ala Val Ser Glu Met Ala Leu Ala Met Gly Phe Met Pro Val Asp Met 180 185 190 Gly Ser Leu Ala Ser Ala Trp Glu Val Glu Ala Met Pro Leu Arg Leu 195 200 205 Leu Pro Ala Trp Lys Val Pro Thr Leu Leu Ala Leu Gly Leu Phe Val 210 215 220 Cys Phe Tyr Ala Tyr Asn Phe Val Arg Asp Val Leu Gln Pro Tyr Val 225 230 235 240 Gln Glu Ser Gln Asn Lys Phe Phe Lys Leu Pro Val Ser Val Val Asn 245 250 255 Thr Thr Leu Pro Cys Val Ala Tyr Val Leu Leu Ser Leu Val Tyr Leu 260 265 270 Pro Gly Val Leu Ala Ala Ala Leu Gln Leu Arg Arg Gly Thr Lys Tyr 275 280 285 Gln Arg Phe Pro Asp Trp Leu Asp His Trp Leu Gln His Arg Lys Gln 290 295 300 Ile Gly Leu Leu Ser Phe Phe Cys Ala Ala Leu His Ala Leu Tyr Ser 305 310 315 320 Phe Cys Leu Pro Leu Arg Arg Ala His Arg Tyr Asp Leu Val Asn Leu 325 330 335 Ala Val Lys Gln Val Leu Ala Asn Lys Ser His Leu Trp Val Glu Glu 340 345 350 Glu Val Trp Arg Met Glu Ile Tyr Leu Ser Leu Gly Val Leu Ala Leu 355 360 365 Gly Thr Leu Ser Leu Leu Ala Val Thr Ser Leu Pro Ser Ile Ala Asn 370 375 380 Ser Leu Asn Trp Arg Glu Phe Ser Phe Val Gln Ser Ser Leu Gly Phe 385 390 395 400 Val Ala Leu Val Leu Ser Thr Leu His Thr Leu Thr Tyr Gly Trp Thr 405 410 415 Arg Ala Phe Glu Glu Ser Arg Tyr Lys Phe Tyr Leu Pro Pro Thr Phe 420 425 430 Thr Leu Thr Leu Leu Val Pro Cys Val Val Ile Leu Ala Lys Ala Leu 435 440 445 Phe Leu Leu Pro Cys Ile Ser Arg Arg Leu Ala Arg Ile Arg Arg Gly 450 455 460 Trp Glu Arg Glu Ser Thr Ile Lys Phe Thr Leu Pro Thr Asp His Ala 465 470 475 480 Leu Ala Glu Lys Thr Ser His Val 485 

1. A method for identifying a compound which inhibits the binding of TSAP6 to one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, having the steps of: a) bringing said compound into contact with a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47 or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48; b) identifying the decrease in and/or the inhibition of the binding between TSAP6 and said protein defined in a).
 2. A method for identifying a compound which makes it possible to increase tumor reversion and/or cell death (apoptosis), characterized in that it has the steps of: a) bringing compounds into contact with a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48; b) identifying the compounds which induce the decrease in and/or the inhibition of the binding between TSAP6 and said protein defined in a); c) bringing the compounds identified in step b) into contact in a system for measuring the phenomena of apoptosis and/or of tumor reversion; d) identifying the increase in tumor reversion and/or in cell death (apoptosis) in said model by comparison with a control model with which said compound has not been brought into contact.
 3. A method for identifying a compound for decreasing and/or inhibiting tumor reversion and/or cell death (apoptosis), having the steps of: a) bringing compounds into contact with a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48; b) identifying the compounds which induce the decrease in and/or the inhibition of the binding between TSAP6 and said protein defined in a); c) bringing the compounds identified in step b) into contact in a system for measuring the phenomena of apoptosis and/or of tumor reversion; d) identifying the decrease in and/or the inhibition of tumor reversion and/or cell death (apoptosis) in said model by comparison with a control model with which said compound has not been brought into contact.
 4. A method for identifying regions of TSAP6 which are involved in the binding with one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, comprising the steps of: a) bringing peptides derived from the TSAP6 protein into contact in a system for determining, in vitro, the binding between TSAP6 and said protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48; b) identifying the peptides which lead to the decrease in the binding between TSAP6 and said protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, in said system.
 5. A method for identifying a product having an activity of increasing tumor reversion and/or apoptosis, characterized in that it comprises the steps of: a) implementing a method as claimed in either of claims 1 and 2, b) modifying the product selected in step a), in particular by grafting residues onto the chemical backbone, c) testing the product modified in step b) in in vitro and/or in vivo methods on relevant models of tumor reversion and/or apoptosis, d) identifying the product which makes it possible to obtain an activity of tumor reversion and/or apoptosis greater than the activity obtained for the product selected in step a).
 6. A method for identifying a product having an activity of decreasing and/or inhibiting tumor reversion and/or apoptosis, characterized in that it comprises the steps of: a) implementing a method as claimed in either of claims 1 and 3, b) modifying the product selected in step a), in particular by grafting residues onto the chemical backbone, c) testing the product modified in step b) in in vitro and/or in vivo methods on relevant models of tumor reversion and/or apoptosis, d) identifying the product which makes it possible to obtain an activity of tumor reversion and/or apoptosis which is decreased compared to the activity obtained for the product selected in step a).
 7. The use of a compound identified using a method as claimed in one of claims 1, 2, 4 and 5, having an activity of increasing tumor reversion and/or apoptosis, for preparing a medicinal product intended for the treatment of cancer.
 8. The use of a compound identified using a method as claimed in one of claims 1, 3, 4 and 6, having an activity of decreasing and/or inhibiting tumor reversion and/or apoptosis, for preparing a medicinal product intended for the treatment of a neurodegenerative disease.
 9. A peptide sequence corresponding to a region of TSAP6 which can be identified using a method as claimed in claim
 4. 10. A nucleotide sequence encoding a peptide sequence as claimed in claim
 9. 11. The peptide sequence as claimed in claim 9, or the nucleotide sequence as claimed in claim 10, as a medicinal product.
 12. The use of a peptide sequence as claimed in claim 9, or of a nucleotide sequence as claimed in claim 10, for preparing a medicinal product.
 13. A complex consisting of a TSAP6 protein and of one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID-No 46 or
 48. 14. A method for inhibiting the binding of TSAP6 to one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, in a cell in vitro, comprising the step of: a) bringing said cell into contact with a compound identified using a method as claimed in claim
 1. 